CN1064685C - Tetrahydrofuran antifungals - Google Patents
Tetrahydrofuran antifungals Download PDFInfo
- Publication number
- CN1064685C CN1064685C CN94195025A CN94195025A CN1064685C CN 1064685 C CN1064685 C CN 1064685C CN 94195025 A CN94195025 A CN 94195025A CN 94195025 A CN94195025 A CN 94195025A CN 1064685 C CN1064685 C CN 1064685C
- Authority
- CN
- China
- Prior art keywords
- compound
- ester
- formula
- ether
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 title description 39
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 title description 19
- 229940121375 antifungal agent Drugs 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 151
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 113
- -1 ester amino acid ester Chemical class 0.000 claims abstract description 96
- 150000002148 esters Chemical class 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 10
- 229920000570 polyether Polymers 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 206010017533 Fungal infection Diseases 0.000 claims abstract 2
- 208000031888 Mycoses Diseases 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 230000001857 anti-mycotic effect Effects 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 241000233866 Fungi Species 0.000 claims description 9
- 239000002543 antimycotic Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 238000003747 Grignard reaction Methods 0.000 claims description 5
- 206010061217 Infestation Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims description 3
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229940057867 methyl lactate Drugs 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 abstract description 2
- 239000010452 phosphate Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 95
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 78
- 239000000243 solution Substances 0.000 description 75
- 239000000047 product Substances 0.000 description 58
- 239000000203 mixture Substances 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 238000010586 diagram Methods 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 238000003756 stirring Methods 0.000 description 36
- 239000002585 base Substances 0.000 description 34
- 239000000460 chlorine Substances 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 239000007788 liquid Substances 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 22
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- 229960001866 silicon dioxide Drugs 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003513 alkali Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 238000005406 washing Methods 0.000 description 17
- JUSXLWAFYVKNLT-UHFFFAOYSA-N 2-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Br JUSXLWAFYVKNLT-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 238000001704 evaporation Methods 0.000 description 15
- 230000008020 evaporation Effects 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 12
- 238000005903 acid hydrolysis reaction Methods 0.000 description 11
- 238000005804 alkylation reaction Methods 0.000 description 11
- 230000000843 anti-fungal effect Effects 0.000 description 11
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 11
- 229960004884 fluconazole Drugs 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 230000029936 alkylation Effects 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000010 aprotic solvent Substances 0.000 description 9
- 238000010265 fast atom bombardment Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 5
- 150000003851 azoles Chemical class 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000001743 benzylic group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 3
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 3
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 3
- 241000228232 Aspergillus tubingensis Species 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 241001527609 Cryptococcus Species 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000006103 sulfonylation Effects 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- 238000009834 vaporization Methods 0.000 description 3
- 230000008016 vaporization Effects 0.000 description 3
- OWBTYPJTUOEWEK-QWWZWVQMSA-N (R,R)-butane-2,3-diol Chemical compound C[C@@H](O)[C@@H](C)O OWBTYPJTUOEWEK-QWWZWVQMSA-N 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical group CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- BNHYDULILNJFFY-UHFFFAOYSA-N 4-[4-(4-nitrophenyl)piperazin-1-yl]phenol Chemical compound C1=CC(O)=CC=C1N1CCN(C=2C=CC(=CC=2)[N+]([O-])=O)CC1 BNHYDULILNJFFY-UHFFFAOYSA-N 0.000 description 2
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- YSAVZVORKRDODB-UHFFFAOYSA-N Diethyl tartrate Chemical compound CCOC(=O)C(O)C(O)C(=O)OCC YSAVZVORKRDODB-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000233870 Pneumocystis Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001149962 Sporothrix Species 0.000 description 2
- 241000223230 Trichosporon Species 0.000 description 2
- 206010061418 Zygomycosis Diseases 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- LPEKGGXMPWTOCB-VKHMYHEASA-N methyl (S)-lactate Chemical compound COC(=O)[C@H](C)O LPEKGGXMPWTOCB-VKHMYHEASA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 201000007524 mucormycosis Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- RLJWTAURUFQFJP-UHFFFAOYSA-N propan-2-ol;titanium Chemical compound [Ti].CC(C)O.CC(C)O.CC(C)O.CC(C)O RLJWTAURUFQFJP-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000007070 tosylation reaction Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- OELRSNSNOLWBST-UHFFFAOYSA-N (2,4-difluorophenyl) 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=CC=C(F)C=C1F OELRSNSNOLWBST-UHFFFAOYSA-N 0.000 description 1
- HFGZFHCWKKQGIS-NOZJJQNGSA-N (2r,3r)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2-ol Chemical compound C([C@@](O)([C@@H](C)S(C)(=O)=O)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 HFGZFHCWKKQGIS-NOZJJQNGSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- RUOPINZRYMFPBF-RXMQYKEDSA-N (3r)-pentane-1,3-diol Chemical compound CC[C@@H](O)CCO RUOPINZRYMFPBF-RXMQYKEDSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- BMRWNKZVCUKKSR-BYPYZUCNSA-N (S)-butane-1,2-diol Chemical compound CC[C@H](O)CO BMRWNKZVCUKKSR-BYPYZUCNSA-N 0.000 description 1
- PUPZLCDOIYMWBV-BYPYZUCNSA-N (S)-butane-1,3-diol Chemical compound C[C@H](O)CCO PUPZLCDOIYMWBV-BYPYZUCNSA-N 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CZGCEKJOLUNIFY-UHFFFAOYSA-N 4-Chloronitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1 CZGCEKJOLUNIFY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- YURNUQQDKASIIJ-UHFFFAOYSA-N CCOClC Chemical compound CCOClC YURNUQQDKASIIJ-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical class C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 101100170601 Drosophila melanogaster Tet gene Proteins 0.000 description 1
- 108010009858 Echinomycin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000223682 Exophiala Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 229930186782 Papulacandin Natural products 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000004990 Smectic liquid crystal Substances 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- XKSZJTQIZHUMGA-KDCKXVQZSA-N [(3'r,4's,5'r,6'r)-3',4,5',6-tetrahydroxy-6'-(hydroxymethyl)spiro[1h-2-benzofuran-3,2'-oxane]-4'-yl] (2e,4e,8e,10e)-7-hydroxy-8,14-dimethylhexadeca-2,4,8,10-tetraenoate Chemical compound O[C@@H]1[C@@H](OC(=O)/C=C/C=C/CC(O)C(/C)=C/C=C/CCC(C)CC)[C@H](O)[C@@H](CO)OC11C2=C(O)C=C(O)C=C2CO1 XKSZJTQIZHUMGA-KDCKXVQZSA-N 0.000 description 1
- VRTQXPCSNPDSLD-UHFFFAOYSA-N [Cl].C1=CNC=N1 Chemical class [Cl].C1=CNC=N1 VRTQXPCSNPDSLD-UHFFFAOYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- MKFJRRMYWGERCT-UHFFFAOYSA-N bihapten 1 dimethyl ether Chemical compound COC1=CC=CC(CCCCCCCCCC2OC(=O)C(=C)C2)=C1OC MKFJRRMYWGERCT-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-M dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)([O-])OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-M 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 150000007520 diprotic acids Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002027 dodecanoic acid esters Chemical class 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000009775 lung immunity Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-GSVOUGTGSA-N methyl (R)-lactate Chemical compound COC(=O)[C@@H](C)O LPEKGGXMPWTOCB-GSVOUGTGSA-N 0.000 description 1
- QCZPJJIXHJSOMY-UHFFFAOYSA-N methyl 2-hydroxypentanoate Chemical compound CCCC(O)C(=O)OC QCZPJJIXHJSOMY-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical group COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- AUJXLBOHYWTPFV-VITLIGDRSA-N n-[(1r,4s,7r,11s,14r,17s,20r,24s)-2,4,12,15,17,25-hexamethyl-29-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-7-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-20-yl]quinoxaline-2-carbo Chemical compound C([C@H](C(=O)N[C@@H](C)C(=O)N1C)NC(=O)C=2N=C3C=CC=CC3=NC=2)OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]2N(C)C(=O)[C@H](C)NC(=O)[C@H](NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]1CSC2SC AUJXLBOHYWTPFV-VITLIGDRSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 108010058641 papulacandins Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- GTDKXDWWMOMSFL-UHFFFAOYSA-M tetramethylazanium;fluoride Chemical compound [F-].C[N+](C)(C)C GTDKXDWWMOMSFL-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical compound O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thermal Transfer Or Thermal Recording In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Lubricants (AREA)
Abstract
A compound represented by the formula (I) wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R1 is a straight or branched chain (C3 to C8) alkyl group substituted by one or two hydroxy moieties, an ether or ester thereof (e.g., a polyether ester amino acid ester or phosphate ester) thereof or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
Description
Background of invention
The present invention relates to tetrahydrofuran antifungals, i.e. (2R-is suitable)-4-(4-(4-(4-(((5-(2, the 4-dihalogenated phenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and tetrahydrofuran (THF)-3-yl) methoxyl group) phenyl)-2,4-dihydro-2-((C that monohydroxy or dihydroxyl replace
3-C
8) alkyl)-3H-1,2,4-triazole-3-ketone replaces anti-mycotic agent, the acceptable ether of its medicine, ester and salt, contains the pharmaceutical composition of above-mentioned each material, and treat and/or prevent with this tetrahydrofuran antifungals and to comprise warm-blooded animal, the particularly suffered fungi infestation of Ren Lei host.
The United States Patent (USP) 5,039,676 of international publication number WO89/04829 that announce June 1 nineteen ninety and A.K.Saksena etc. discloses (±) genial (±) the resistance fungi compound with the following formula representative
In the formula, X=F, Cl; Z=low alkyl group, 2-low alkyl group-3-oxygen-1,2, the C that the 4-triazole-the 4-base replaces
2-C
8Alkyloyl or phenyl, such as have (±)-genial (±) anti--1-(4-((2-(2,4 difluorobenzene base)-2 ((1H-1,2,4-triazol-1-yl) methyl) tetrahydrochysene-4-furyl) methoxyl group) phenyl)-4-(1-methylethyl) piperazine.Yet, WO89/04829 and unexposed compound of the present invention.
The European patent publication No.05399381 that owns together that announced on May 5th, 1993 disclose such as ((5R)-(((((5-(2 for 4-for 4-for 4-for suitable-4-, the 4-dihalogenated phenyl)-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group tetrahydrofuran (THF)-3-7 yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-(C
1-C
10) alkyl)-3H-1,2,4-triazole-3-ketone anti-mycotic agent, but and unexposed compound of the present invention.
The United States Patent (USP) 4 of Janssen, 791,111 disclose such as (+) suitable-4-(4-(4-(4-((2-2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl methyl)-1,3-dioxolane-4-yl) methoxyl group) phenyl)-the 1-piperazinyl)-2,4-dihydro-2-(2-hydroxyl-1-methyl-propyl)-3H-1,2,4-triazole-3-ketone is as antiseptic-germicide, and has the solubleness of increase, but it and unexposed The compounds of this invention.
For having increase solubleness, and to therapy system fungi infestation, particularly the infection of mould Pseudomonas, Candida, cryptococcus and opportunistic pathogen is had the broad-spectrum antifungals that excellent activity distributes demand is arranged.
Summary of the invention
In the formula, X represents independently all to be F or all to be Cl, and perhaps X is F and another is Cl independently independently;
R
1Straight or branched (the C that is replaced by one or two hydroxyl
3-C
8) alkyl, or its steric isomer, or its ester or ether, or the acceptable salt of its medicine.
Of the present invention one preferred aspect, the compound of a class by the representative of formula II proposed, its ester or ether, or the acceptable salt of its medicine.
X is F independently or is Cl in the formula, and perhaps an X is F independently, and another is Cl independently;
R in the formula
2Be H or C
1-C
3Alkyl, R
3By the C of a hydroxyl replacement
1-C
3Alkyl, have asterisk (
*) carbon have the absolute configuration of R or S.
Another preferred aspect, the present invention proposes a kind of compound by formula III representative, its ester or ether, or the acceptable salt of its medicine.
R wherein
5Be
Aspect another, a kind of compound by the representative of formula IV has been proposed, its polyether ester, its phosphoric acid ester, its sulfuric ester, its heterocyclic ester, its alkanoates, its chain acid ester, its amino acid ester, its acid ester or the acceptable salt of its medicine of the present invention.
Wherein
Or
Here R
6Be H.
The present invention and DESCRIPTION OF THE PREFERRED
The term of Shi Yonging is " by 1 or 2 C that hydroxyl replaces in this article
3-C
8Alkyl " mean the straight or branched alkyl of 3 to 8 carbon atoms; and it includes but not limited to methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, sec-butyl, isobutyl-, the tertiary butyl, n-pentyl, sec.-amyl sec-pentyl secondary amyl, isopentyl, tert-pentyl, neo-pentyl, n-hexyl, Sec-Hexyl, isohexyl, uncle's hexyl, new hexyl, n-heptyl, Zhong Gengji, different heptyl, uncle's heptyl, new heptyl, n-octyl, secondary octyl, iso-octyl, uncle's octyl group, the new octyl group that one or two hydroxyl replaces, and comprises these C
3-C
8The R of alkyl and S steric isomer.
Term " C that hydroxyl replaces
1-C
3Alkyl " mean
With-(CH
2)
3-OH wherein have asterisk (
*) carbon atom have R or the absolute configuration of S.
Term " the C that hydroxyl replaces
4Or C
5Alkyl " mean
Wherein each have asterisk (
*) carbon R or the absolute configuration of S are all arranged.
Term " the acceptable ether of medicine " means (a) 1-20 carbon, preferred 1-8 carbon, the more preferably straight chain and the branched alkoxy of 1-6 carbon; (b) general formula is-O-(CHR
7)
n-Ar (R wherein
7Be C
1-C
6Straight chain and branched-chain alkyl, the preferred 1-3 of n=0-6, Ar are particularly chlorine and fluorine or nitro, cyano group and the trihalogenmethyl phenyl that replace of trifluoromethyl particularly of phenyl, halogen) aryl (C
1-C
6) alkoxyl group.Most preferred ether comprises methoxyl group and benzyloxy.
Term " ester " means (a) polyether ester; (b) phosphoric acid ester; (c) heterocyclic ester; (d) alkyl carboxylic acid and thiazolinyl carboxylicesters; (e) amino alkane carboxylicesters and (f) acid ester and (g) sulfuric ester.Term used herein " polyether ester " means by general formula
The polyether ester of representative, wherein R
7As defined herein, s is the integer of 1-6, preferred s=1-3, more preferably s=1; T is the integer of 1-6, preferred t=1-3, more preferably t=2 or 3.R
8Be R
7Or-(CHR
7)
s-CO
2R
7Preferred R
8Be CH
3Or C
2H
5Or-CH
2CO
2H or-CH
2CO
2CH
3, the polyether ester that is suitable for generally comprises-COCH
2O (CH
2CH
2O)
1CH
3-COCH
2O (CH
2CH
2O)
2CH
3And-COCH
2O (CH
2CH
2O)
3CH
3
Term used herein " phosphoric acid ester " means by general formula
The phosphoric acid ester of representative, wherein Z is 0 or 1; R
7Define preferred H as this paper front; N is the integer of 0-6; M is 0 or 1, and W is H, CH
2Ar or
And Ar such as this paper front define herein.Suitable phosphoric acid and ester generally comprise
Or
Or the acceptable salt of their medicines, m=n=1-4 here.
Term used herein " heterocyclic ester " means by general formula
The heterocyclic ester of representative, wherein R
7Define as this paper front, W is the integer by 1-5, and preferred W is 1-3; Q=3 or 4; Y is CHR
7,-O-,-NH-,-NR
7-,-S-,-SO-or-SO
2-.
" alkyl carboxylic acid ester and thiazolinyl acid esters " used herein means randomly by hydroxyl or the straight or branched alkyl carboxylic acid ester of ether replacement or the mixture of thiazolinyl carboxylic acid ester groups or these alkyl carboxylic acid esters or thiazolinyl carboxylicesters.
Preferred alkyl carboxylic acid ester comprises acetic ester to the dodecanoic acid ester, and particularly acetic ester is to butyric ester.Preferred hydroxyl substituted alkyl carboxylicesters comprises hydroxyl group, particularly
The C that replaces
1-C
8The alkyl carboxylic acid ester.Preferred thiazolinyl carboxylicesters is C
10-C
20The thiazolinyl carboxylicesters.Comprise C
14-C
18The thiazolinyl carboxylicesters is as suitable-7-cetene acid esters.
" amino alkane carboxylicesters " used herein comprises natural and amino-acid residue synthetic, and preferably its amino that has is subjected to the amino-acid residue of known traditional protection base of prior art professional such as phenyl acetate protection.
Term used herein " acid ester " means by general formula
One class acid ester, R here of representative
7Define as this paper front, K is the integer of 1-8.The acid ester that is suitable for generally comprises oxalic acid, propanedioic acid, succsinic acid, pentanedioic acid and hexanodioic acid, and the side chain diprotic acid as
Monoesters.
Term used herein " ether " means the C that generally makes by known Williamson ether synthesis method
1-C
6Alkyl or aryl (C
1-C
6) alkyl.The ether that is suitable for generally comprises methyl and benzyl.
Compound of the present invention and their ester and ether demonstrate broad-spectrum antifungal activity to candidiasis, other yeast, dermatophytes, aspergillus tubigensis and opportunistic diseases fungi in various in vitro testss.In Sabouraud liquid of glucose substratum (SDB) medium, multiple fungi has been carried out the extracorporeal antifungal activity test by traditional agar dilution.Measuring media inhibition concentration (MIC) after 24,48 and 72 hours test.
Term " opportunistic pathogen " comprises cryptococcus, histoplasma capsulatum, blastomycete, ball bud daughter bacteria, sickle spore bacterium, mucormycosis, blastomyces brasiliensis, product look blastomycete, Wangiella, sporothrix, Pneumocystis bacterium, trichosporon bacteria etc., they at suitable animal species such as mouse, big white mouse or exempt from all to demonstrate in the son activity in vivo.Expect bacterium, protozoon, Gram-negative bacteria, gram-positive microorganism, anerobe, Legionella, burgdorferi, mycoplasma, treponema, Gardner Salmonella, trichomonas and the trypanosome of compound of the present invention to many genus, kind.
R in formula
5The C that=hydroxyl replaces
4And C
5The preferred formula III compound of alkyl to 37 kinds of aspergillus nigers, flavus, Aspergillus fumigatus and terreus, shows following extracorporeal antifungal activity: geometric mean MIC in SDB
sBe≤0.05 to 〉=1.53 (mcg/ml) geometric mean MFC
sBe 0.27 to 〉=4.24 (mcg/ml).
R in the formula
5C for the hydroxyl replacement
5The preferred formula III compound exhibits of alkyl goes out:
(1) anti-mycotic activity more excellent than fluconazole, this can by Candida albicans (N=26), Crewe Si Shi read coccus (N=26), do not have a hair candidiasis (N=9), coccus (N=4) is read in the torrid zone, the starlike thought in the various in vitro testss that coccus (N=1), Cryptococcus neoformans (N=3) and dermatophytes, T rubrumT menta and T tonsurans (N=6) carry out, the geometric mean MIC and the MFC that obtained after 48 or 78 hours record;
(2) in following body inner model, demonstrate more excellent anti-mycotic activity: in the mouse model (PO-1XDX4D) of lung's immunity loss, flavus is compared with other azoles such as itraconazole with Aspergillus fumigatus (four strains); And in Candida albicans (4 strain) system model of normal and damaged white mouse (PO-1XDX4D) with other azoles, compare as fluconazole.
In white mouse aspergillus tubigensis pulmonary infection model, the oral in vivo anti-mycotic activity and the azoles of The compounds of this invention are such as suitable with fluconazole.What use is that people such as David Loedenberg is entitled as " Sch42427, The Active Enantiomer of Antifunal agentSch39304 in publication " Antimicrobial Agents and Chemotherapy (1992), 36498-501 "; In vitro Activty " article described in method.The european patent application book No.0 that announces on May 5th, 1993,539, also narrated flavus pulmonary infection model among the 938Al.
In SDB, the preferred compound of formula III is compared with following compounds to show has better external antifungal property to 37 kinds of aspergillus: (a) its geometric mean MIC
sBe≤0.05 to≤0.81, and the geometric mean MIC of fluconazole 〉=32; (b) its geometric mean MFC
sBe≤0.89 to≤3.78, and the geometric mean MFC of fluconazole 〉=32.
Following table Q, R demonstrate with fluconazole with S and compare, and three kinds of preferred formula III compounds have better extracorporeal antifungal activity.Table Q represents that these three kinds preferred formula III compounds are with various MIC
sThe anti-mycotic activity that the per-cent of the fungi strain number of≤1mcg/ml is represented and the comparison of fluconazole.Table R represents with identical MFC
sThe anti-mycotic activity that≤1mcg/ml bacterial strain per-cent is represented.Table S represents for these three kinds preferred formula III compounds the numerical value as the external MIC90 of listed same microorganism among table Q and the R.
In formula
Most preferably formula III compound than azole compounds with similar structures, when using the oral administration prescription of methylcellulose gum, all the time all demonstrate higher serum content on one's body mouse, white mouse, dog and monkey, also demonstrate very long oral back serum half-life and favorable tissue distributivity.Above listed most preferably formula III compound rat model in an organism be not the inductor of various cytochrome P-450 liver drug metabolism enzyme after oral.
2.F
7=fluconazole
The ester of the The compounds of this invention of preferred formula IV and ether also demonstrate good in vivo anti-mycotic activity to the fungi of very wide scope.After or intestines external administration input ratio such as compound IV oral for mouse, big white mouse, dog and monkey, below the ester of preferred formula IV compound and ether are listed in, R wherein
9Be:
The easy in vivo metabolism of preferred hereinbefore ester becomes corresponding alcohol, such as R
5Be
But most preferred metabolism ester comprises R in the formula
9Be the formula IV compound of following each group:
The antifungal compound of the present invention of formula I representative, on the tetrahydrofuran (THF) ring with dihalo-phenyl and 1H, 1,2, has R absolute stereo chemistry configuration on the carbon atom that 4-triazol-1-yl-methyl two segment bases groups links to each other, and a CH
2The OY chain link has and 1H, and 1,2,4-triazol-1-yl-methyl chain is the stereochemistry configuration of " cis ".Ask for an interview as shown in the formula I
R in the formula
1By 1 or 2 straight or branched C that hydroxyl replaces
3-C
8Alkyl, it preferably exists with the form of one stereoisomers, but stereoisomer mixture is also within desired extent of the present invention.
Capable and walk to generality among the embodiment 68 of 52 hurdles, 44 row on the 5th hurdle, 16 but not the open formula I compound in specificity ground is " cis " series, ii class at the 9th hurdle, the 59-68 of people's such as Saksena United States Patent (USP) 5,039,676.
General synthetic preparation
Can use the series of steps of being narrated in synoptic diagram I-V below to prepare compound of the present invention.In the synoptic diagram I, be easy to prepare compound 3 by commodity compound 1 according to embodiment 1a, 1b and 1c.By at tetraisopropoxy titanium (i-PrO)
4Ti exists following, in aprotic solvent such as methylene dichloride, prepares compound 4 0-35 ℃ of following the reaction by L (+) diethyl tartrate (L-DET) and molecular sieve.Ask for an interview such as T.Katsuki, K.B.Sharpless at J.Am.Chem.Soc. 102,5974 (1980); With 103,464 (1981) in narration.(step d) on the synoptic diagram adds oxygenant, such as tertbutyl peroxide (TBHP) at this reaction mixture.When using L (+) diethyl tartrate, add the compound of compound 3 with regard to production 4.Under 0-80 ℃, in aprotic solvent such as DMF, in the presence of highly basic such as NaH, compound 4 and 1H-1, the reaction of 2,4 triazoles just obtains the diatomic alcohol compounds of formula 5.At alkali such as triethylamine (Et
3N) exist down, in aprotic solvent such as methylene dichloride, compound 5 with such as methylsulfonyl chloride (MsCl) reaction, the primary hydroxyl of compound 5 just is converted into residue, as methanesulfonates or tosylate (compound 6).At room temperature, in aprotic solvent such as DMF, handle compound 6 and just obtain ethylene oxide compound 7 with highly basic (NaH).Under 25-75 ℃, in the presence of highly basic such as NaH, in aprotic solvent such as DMCO, 7 with diethyl malonate reaction, obtain lactone 8.Alcohol as ethanol (EtOH) in usefulness metal hydride such as lithium borohydride (LiBH
4) reduction 8, obtain trivalent alcohol compound 9.At alkali such as Et
3N exists down, in aprotic solvent such as THF, allow 9 with excessive toluene sulfonyl chloride reaction, two primary alconols with 9 are converted into residue (methanesulfonates or tosylate), obtain two (toluenesulphonic acids) ester 10.Under 100-120 ℃ high temperature, in aprotic solvent such as toluene, allow compound 1O contact with highly basic such as NaH, obtain the mixture of two kinds of tosylates (cis and trans), with chromatogram they are separated, obtain cis tosylate 11, under 25-75 ℃ temperature, in the presence of highly basic such as NaH, in aprotic solvent such as DMSO, make compound 11 and pure HOY reaction, just obtain formula I compound.
The synoptic diagram II provides the another kind of reaction sequence that obtains The compounds of this invention.In the presence of NaH, compound 11 and commodity compound 12 reactions obtain compound 13.In the presence of propyl carbinol, the hydrolysis with highly basic such as NaOH finish N-ethanoyl in 13 obtains compound 14.Should be clear, as without the N-ethanoyl in the compound 12, also can provide the corresponding N-formyl and the N-benzoyl derivative of compound 13 as N-formyl radical, N-benzoyl with any other alkaline unstable group.At salt acid scavenger such as K
2CO
3Exist down, 13 with the parachloronitrobenzene reaction, obtain nitro-compound 15.In the presence of platinum or palladium catalyst, carry out catalytic reduction, obtain amine 16 15.In the presence of pyridine, handle 16 with phenyl chloroformate, obtain amino formate intermediate 17.17 produce Urea,amino-18 with hydrazine reaction, its cyclisation are obtained the triazolone 19 of key in the presence of FORMAMIDINE ACETATE.Carry out alkylation according to embodiment 19 and 20, obtain comprising the compound of the structure 20 of formula I compound, R in the formula
1Define as the front.
The synoptic diagram III provides the stereospecific synthesis method that zymochemistry obtains cis alcohols 26 and cis tosylate 11 of using.Such as, three alkylol cpds 9 react in the presence of porcine pancreatic lipase with vinyl acetic monomer, obtain one monoacetate 21.Use the acid instability group,, obtain compound as 22 as remaining primary hydroxyl in the THP trtrahydropyranyl protection 21.Make acetoxyl group hydrolysis in 22 with alkali such as KOH, obtain 23.Each remaining step is: (i) with compound 23 tosylations, obtain 24; (ii) in the presence of NaH, 24 cyclisation are obtained 25; (iii) with an acidic catalyst such as tosic acid the THP ether in 25 is separated protection, obtain 26,26 tosylations that will obtain again obtain key intermediate 11.
At the U.S. Patent Application Serial Number No.08/055 that owns together, being described in detail of preferred preparation method of key intermediate disclosed in 268 (submissions on April 30th, 1993), this patent is hereby incorporated by.
The synoptic diagram I
The synoptic diagram II
Synoptic diagram II (continuing)
Reactant: (a) NaH; (b) NaOH/ propyl carbinol; (c) p-Cl-C
6H
4NO
2/ K
2CO
3/ DMSO; (d) H
2/ PVC; (e) C
6H
5OCOCl/ pyridine/CH
2Cl
2(f) NH
2NH
2/ H
2The O/ diox; (g) FORMAMIDINE ACETATE DMF/ heating (h) is according to embodiment 19 and 20
D20
The synoptic diagram III
Reactant (a) porcine pancreatic lipase/EtOAc; (b) dioxy pyrans/H
+(c) KOH; (d) toluene sulfonyl chloride/pyridine; (e) NaH; (f) methyl alcohol/H
+(g) toluene sulfonyl chloride/pyridine.
The synoptic diagram V
The synoptic diagram VI
(a) pyrrolidone, room temperature, (b) R
1x-X.NaH.DMF:(c) RED-AL. toluene .-20 °, (d) H
2NNHCHO.MeOH:(e) R
2xMgBr.Et
2O ,-10 ℃ of room temperature 24h; (f) (g) H of 17F in the synoptic diagram V and embodiment 32d
2, Pd.HCOOH, 80 ℃. and method; The preparation of synoptic diagram VII polyether ester
1DCCD=dicyclohexyl carbonization diamines DMAP=4-(N, N-dimethylamino) pyridine
The table of figure VII
The table of figure VII
42 43 45 M.S.CH
3(OCH
2CH
2) OH ClCH
2CO
2Na-COCH
2O (CH
2CH
2O) Me 817CH
3(OCH
2CH)
2OH ClCH
2CO
2Na-COCH
2O (CH
2CH
2O)
2Me 861CH
3(OCH
2CH
2)
3OH-ClCH
2CO
2Na-COCH
2(CH
2CH
2O)
3Me 905HO
2C (OCH
2CH
2)
2OH ClCH
2CO
2Na-COCH
2O (CH
2CH
2O)
2COOH 905
42 | 43 | 45 | M.S. |
X | M- | ||
- | PGOCH 2CO 2H PG=blocking group is as CH 2Ph | COCH 2OH | 759.3 |
CH 3(OCH 2CH 2) 3OH | ClCH 2CO 2H | COCH 2O(CH 2CH 2O) 3Me | 905 |
Phosphoric acid ester
Figure VIII B
The table of figure VIII A
X=F
The table of figure VIII B
Figure VIII C
The preparation of synoptic diagram IX heterocyclic ester
The table IX of figure IX
The synoptic diagram IV proposes a cover response procedures again and obtains compound of the present invention.Methyl ether by 12 carries out the reaction of step a-g in the synoptic diagram II, prepares compound 27 by the methyl ether of compound 12 in the synoptic diagram II.Compound 27 and HBr or BBr
3Reactant aqueous solution obtains phenolic compound 28.Compound 28 reacts with 1 normal NaH at ambient temperature, uses then such as silica-based ethoxyl methyl chlorine of 2-(trimethylammonium) (SEM-Cl) and DMF and handles, and obtains the compound 29 of SEM nitrogen protection.With compound 29 deprotonations, then at high temperature, negatively charged ion that will so form in DMF or DMSO and tosylate reaction generate compound 30 with NaH.By such as using 6N methyl alcohol HCl solution-treated 3 hours at ambient temperature, remove 30 chlorine blocking group, such as SEM, obtain compound 19.Handle compound 19 at 20 ℃ with NaH and DMSO and reach 3/4 hour, use R then
1The X alkylation just obtains compound 1.At R
1R among the X
1Be the C that to have a protected hydroxyl chain link at least be O-SEM
3-C
8Alkyl, X are residues, such as are that the bromo-benzene sulfonic acid root is removed hydroxyl protecting group by the methyl alcohol HCl solution such as 6N from compound 31, such as O-SEM, have just obtained the The compounds of this invention of formula I.
The synoptic diagram V provides a preferred routes for the preparation process of listed The compounds of this invention in the synoptic diagram II.By the sodium salt that in anhydrous DMSO, makes 4-(4-(4-nitrophenyl)-1-piperazinyl) phenol and NaH reaction prepare compound 31 in 30 minutes at 50-60 ℃, again 50-70 ℃ make itself and 2,4-difluorophenyl tosylate 11F (compound 11 of X=F in the synoptic diagram II) reaction 1 hour obtains compound 15F (compound 15 of X=F in the synoptic diagram II) after fast silica gel chromatogram or crystallization.In containing the ethanol of 1NHCl, hydrogenating reduction 15F obtains aminocompound 16F (compound 16 of X=F in the synoptic diagram II) in the presence of 5% Pd/C.At 0-5 ℃, in anhydrous pyridine, reacted 2 hours with phenyl chloroformate and 16F, obtain phenyl carbamate 17F (compound 17 of X=F in the synoptic diagram II).At 80 ℃, 17F and hydrazine hydrate be 1, and reaction is 4 hours in the 2-glycol dimethyl ether, obtains Urea,amino-18F (compound 18 of X=F in the synoptic diagram II), in the reactor that stirs, under 80 ℃ and dry argon gas protection, makes 18F and FORMAMIDINE ACETATE and Et
3N reacts in 2-methyl cellosolve and spends the night, and obtains 3H-1, and 2,4-triazole-3-ketone 19F (compound 19 of X=F in the synoptic diagram II).According to the program of synoptic diagram IV, compound 19 (f) and R
1The X reaction just obtains the compound of formula I.
The synoptic diagram VI proposes the route that another space is selected for preparation preferred compound of the present invention.In room temperature, in methylene dichloride, make compound 35 (such as the S-methyl lactate) contact 24 hours with excessive tetramethyleneimine, obtain acid amides 36.36 obtain 37 with NaH in DMF with such as Benzyl Chloride reaction, at-20 ℃ of two (2-methoxy ethoxy) aluminium chlorhydrate sodium salt (" RED-AL ") toluene solutions with 3.4M acid amides 37 is carried out selective reduction, obtain aldehydes 38.Aldehyde 38 and H
2NNHCHO reacts in methyl alcohol and obtains 39, and it is at-10 ℃-room temperature Yu Geshi reagent react in anhydrous diethyl ether, such as ethylmagnesium bromide reaction 24 hours, just obtains 40, S wherein, and S isomer: S, the ratio of R isomer is 94: 6.When carrying out grignard reaction in the presence of 1.2 normal two (trimethyl silicon based) ethanamide, SS: the SR ratio is 99: 1.At 80 ℃, in toluene, exist down at DBU (1,8-diazabicylo (5,4,0) 11 carbon-7-alkene), make the compound 17F reaction 6 hours of compound 40 and synoptic diagram V, elevated temperature carries out cyclisation to 100-11O ℃, continues to keep this temperature overnight.After the thin-layer chromatography purification, obtain 20F.Usefulness hydrogen and the palladium black processing 20F in the formic acid methyl alcohol of containing being heated to 60 ℃ obtains crude product, and purifying with its separation and with thin-layer chromatography obtains compound 20F, promptly in formula
Formula III compound.
Tetrahydroform 39 being carried out grignard reaction produce 40, is identical (being the S type) on 40 new chiral centre inductive absolute space chemistry and chiral carbon 39 substantially wherein.Here use " being identical substantially " this term to mean S: the ratio of S and S: R (in such as 40) was preferably greater than 15: 1 greater than 9: 1, most preferably was at least 99: 1.
Herein with M
+The mass-spectrometric data of expression is the parent ion that is recorded by fast atom bombardment technology (FAB), and represents the M+1 peak.
The synoptic diagram VII proposes the general method of the polyether ester of preparation alcohol of the present invention.By 42 with excessive soda ash such as NaH under the ice bath temperature, reaction just is prepared into alcohol ether 42 (as CH in anhydrous ether such as THF
3(OCH
2CH
2)
3OH, i.e. R in the formula
7=H, the compound 42 of t=3) alcoholate.The reaction mixture that obtains is like this stirred several hrs, as 2 hours or more, then to the sodium salt that wherein adds acid 43, as sodium chloroacetate (be LG=Cl in the formula, R
7=H, S=1 43).The reaction mixture that will so form under the ice bath temperature stirs, and along with allowing temperature rise to room temperature, continues to stir.The careful water that adds separates pfpe acid 44 and purification with ordinary skill in reaction mixture.
44 at CH
2Cl
2Solution in add in 1.3-1.5 normal alkali 4 (N, N-dimethylamino) pyridine (DMAP) and the formula
20F.The temperature of the reaction mixture that the use ice bath will so form descends, to wherein adding the normal dicyclohexyl carbonization of 1.3-1.5 diamines (DCCP).Continue to stir the reaction mixture that so obtains, the limit allows temperature rise to room temperature.Remove the precipitation of urea and use the conventional art separated product, the residue with silica gel chromatography is purified and so obtained obtains FAB and records (M+H)
+=906 pure compound.Carry out suitable substituting with different raw material 42 and 43, prepare and show to go up listed various immunomodulator compounds 45 in the synoptic diagram VII.Use FAB to measure the MS value of showing to go up listed each product in 45 1 hurdles in the synoptic diagram VII.
Synoptic diagram VIII A-C has listed the general preparation method of alcohol phosphate of the present invention.Synoptic diagram VIII A has proposed R in the formula
6For
The preparation method of the phosphoric acid ester of the formula IV compound during z=m=n=o.In room temperature, in methylene dichloride, make the compound 20F and the 1.5 normal N of synoptic diagram II, N-di-isopropyl dibenzyl phosphamide, 1.5 equivalent tert-butyl peroxides (isooctane solution of 3M) and alkali such as tetrazolium reaction several hours.With silica gel thin-layer chromatography (5% methyl alcohol: EtoAcv: the v) process of following response.Wash the thick product that is dissolved among the EtoAc with hypo solution, purify with standard technique again, obtain dibenzyl phosphate 46.In room temperature, be dissolved in isopyknic ethanol and the Glacial acetic acid 46, spend the night under nitrogen atmosphere, stirring in the presence of the excessive 10%Pd/C, remove 46 dibenzyl ester group and obtain 47.Continue reaction until with till thin-layer chromatography (or NMR) is not when can surveying raw material.Remove by filter catalyzer, with standard technique purification raw phosphoric acid ester 47.At room temperature, in methyl alcohol with 2 normal alkali such as NMG (or Et
3N) handle 47 and obtain 47.2NMG.46 and 47 compounds according to synoptic diagram VIII A preparation are listed in the table of synoptic diagram VII A.
Synoptic diagram VIII B has represented in the formula
Z=m=1, the preparation method of the phosphoric acid ester of the formula IV of n=0.With 1.3 normal DMAD, 1.3 normal DCCD and 1.3 normal general formulas be
Acid 49 (such as HO
2C (CH
2)
4Br, i.e. z=1, n=4, R
7=H residue LG is Br) handle the compound 20F be dissolved in methylene dichloride.At room temperature reaction stirred is till can't check raw material with thin-layer chromatography, and the purification crude product obtains bromide 50, and this is R in the formula
1=
White solid.Bromide 50 is dissolved in the benzene, with 1.5 normal dibenzyl Trisilver phosphates (St, the commodity of the Sigma chemical company of Louis) together 80 ℃ of following heated overnight.Reaction mixture is with alkali such as K
2CO
3Solution washing.Separate thick product, purifying with silica gel column chromatography obtains dibenzyl phosphoric acid salt 51.At room temperature, under nitrogen atmosphere, be dissolved in 51 of ethanol/Glacial acetic acid and spend the night, obtain phosphoric acid ester 52 with excessive 10%Pd/C processing.In methyl alcohol with 2 normal alkali such as NMG (or Et
3N) handle 52 and obtain 52.2NMG.
Synoptic diagram VIII C has proposed R in the formula
6Such as among the front view VIII B definition, z=1, the another kind of preparation procedure of the formula IV phosphoric acid ester of n=1.At room temperature will be dissolved in methanol aqueous solution and excess base such as K
2CO
3Methyl acetate benzylic ether 53 stir and spend the night, obtain benzylic ether 54.At room temperature solution and 1.3-1.5 normal DCCD and the DMAP reaction of 20F and 54 in methylene dichloride spent the night, obtain ester 55.At room temperature, the excessive 10%Pd/C processing that is used under nitrogen atmosphere in ethanol-Glacial acetic acid is spent the night, and removes 55 carbobenzoxy.The thick product of purifying obtains 56.Handle 56 according to the program of synoptic diagram VIII B with 1.5 normal di-isopropyl phosphate dibenzyl esters and 1.5 normal tert-butyl peroxides and tetrazolium and obtain dibenzyl ester 57.Under nitrogen atmosphere, in ethanol-Glacial acetic acid, remove dibenzyl (as mentioned above) and obtain phosphoric acid ester 58 with 10%Pd/C.Handle 58 with 2 equivalent alkali such as NMG and obtain 58.2NMG.
The preparation method of synoptic diagram IX explanation heterocyclic ester of the present invention.Under 0-5 ℃ temperature, in the presence of alkali such as pyridine, will be dissolved in the formula of methylene dichloride
Compound 20 usefulness compounds 62 (wherein Hal=Br or Cl, w=1-5 such as Cl-CH
2COCl) handled 4 hours.Reactant is placed on refrigerator overnight.Can add compound 62 and alkali if necessary, reaction last till can not detect 20F with thin-layer chromatography till.With the silica gel column chromatography crude product of purifying, obtain pure 59 (w=1, Hal=Cl).Under 50-60 ℃, make 59 with excessive nitrogen-containing heterocycle compound 60 (as Y=NH, R
7=H, q=4) reaction obtained 61 in 1 hour.Just obtain below the synoptic diagram IX listed compound in the table with 5 yuan or 6 membered ring compounds such as morpholine, N-methyl piperidine substituted nitrogen-containing heterocyclic compound 60.
The alkyl carboxylic acid ester and the thiazolinyl carboxylicesters that generally prepare 20F by the synthetic technology of standard, such as in the presence of alkali such as pyridine, the acid anhydrides by alkyl carboxylic acid or thiazolinyl carboxylic acid or the reaction of carboxylic acid halides just obtain the alkyl carboxylic acid ester or the thiazolinyl carboxylicesters of formula I compound.
The alkylol cpd of through type I-IV is at 70-90 ℃, in the presence of excess pyridine with sulphur trioxide reaction at least 2 hours, according to people such as R..M.Moriarty at Tetrahedron Letters, Vol.35, the method that proposes among the No.44, P8103-8106 (1994) can prepare sulfuric ester.
In aprotic solvent such as DMSO, in the presence of highly basic such as NaH, but be the also preparation of alcohol reaction of HOY by compound 11 and general formula,
(R)-tosylate series asks for an interview X=F or Cl in embodiment 15 formulas
R
1=by 1 or 2 C that the hydroxyl chain link replaces
3-C
8Alkyl.
The compound exhibits of formula I representative goes out very wide anti-mycotic activity spectrum, in traditional anti fungal screening test, can resist following people and animals pathogenic bacterium: aspergillus tubigensis, blastomycete, candidiasis, cryptococcus, coccidioides immitis, Epidermophyton, product look blastomycete, sickle spore bacterium, mucormycosis, yeast, torulopsis bacterium, trichophyton, trichosporon bacteria, sporothrix and Pneumocystis.
The preferred compound of formula IV demonstrates the anti-mycotic activity of topical, oral and enteron aisle external administration in living animal test, this activity is better than existing anti-mycotic agent unexpectedly, such as itraconazole, fluconazole and by people such as Saksena at United States Patent (USP) 5,039,676 and international publication number WO93/09114 in disclosed azole compounds.
The antifungal compound of expection formula I and pharmaceutical composition of the present invention can show antianaphylaxis, anti-inflammatory and immunoregulatory activity, wide spectrum anti-infection activity, such as antibacterium, protozoacide and anthelmintic activity.
The present invention also provides a kind of composition that is used for the treatment of or prevents fungi infestation, and it contains compound and the acceptable salt of medicine and their drug acceptable carrier or the thinner of the formula I representative of anti-mycotic efficiency quantity.
Pharmaceutical composition of the present invention also can contain other antifungal compound of anti-mycotic efficiency quantity, such as the cell walls active compound, term used herein " cell walls active compound " means the compound of any interference fungal cell wall, it includes but not limited to papulacandin, Quinomycin A and A Ku bleomycin and as the fungal cell wall inhibitor of fumanomycin and so on, such as fumanomycin K and United States Patent (USP) 5,006,513 described other fumanomycin, this patent is hereby incorporated by.
The drug acceptable salt of The compounds of this invention comprises acceptable acid-adducting salt of medicine and alkali adduct.
It is the mineral acid that adds number of computations in The compounds of this invention that preferred medicine can be accepted acid-adducting salt, as HCl, HBr, H
2SO
4, HNO
3Or H
3PO, or organic acid are as formed non-toxic acid adducts such as alkyl or aryl sulfonic acid methylsulfonic acid, ethylenehydrinsulfonic acid, tosic acid, naphthene sulfonic acid.
Be applicable to that it is the compound that can form drug acceptable salt with the acidic drug acceptable ester of the antifungal compound of formula I, II, III or IV that medicine of the present invention can be accepted alkali, it comprises suitable organic and mineral alkali.Suitable organic bases comprises primary, the second month in a season, alkyl amine, alkyl alcoholamine, arylamine, alkylarylamine and cyclammonium.The example of organic amine comprises and is selected from chloroprocaine, PROCAINE HCL, PHARMA GRADE, piperazine, glucosamine, N-methyl glucoside amine, N, N-dimethyl glucose amine, quadrol, diethanolamine, Diisopropylamine, diethylamine, N-tolylene diamine, N-benzyl-2-phenyl-ethyl amine, N-n ' dibenzyl-ethylenediamin, choline, chlorine imidazoles, triethylamine (ET
3N), three (methylol) aminomethane, or the acceptable alkali of medicine of D glucosamine etc.Preferred organic bases comprises N-methyl glucoside amine (NMG), diethanolamine and three (methylol) aminomethane (TRIS).Most preferably use 2 normal NMG in the present invention.Suitable mineral alkali also comprises alkali metal hydroxide, as NaOH.
Pharmaceutical composition of the present invention is applicable to any mode of taking, such as oral, enteron aisle external administration, such as subcutaneous injection, intramuscular injection, intravenous injection and intraperitoneal medication, surface administration or vagina administration, perhaps suck (mouthful or nose) administration, can be by the drug acceptable salt of the formula I compound of formula I compound or equivalent and suitable acceptable inert support of medicine or thinner be combined to form prescription.
The example of suitable composition comprises and is used for oral solid or liquid composition, such as tablet, capsule, pill, pulvis, particle, solution, suppository, lozenge, lozenge, suspension or emulsion.Solid carrier can be one or more materials that also can be used as thinner, perfume compound, solubility promoter, lubricant, suspension agent, tackiness agent or tablet disintegrant, also can be a kind of one-tenth capsule thing.In pulvis, carrier is a kind of finely divided solid, and it and finely divided active compound mix.In tablet, active compound mixes with the carrier with necessary cementability with suitable proportion, is pressed into desired shape and size again.
Can give medicament shape according to known method preparation surface in the prior art, it can contain various compositions, vehicle and additive.The prescription of surface administrable comprises ointment, fat, lotion, aerosol, pulvis, vaginal suppository and spray.
In order to prepare suppository, earlier a kind of low-melting wax is melted such as mixing-in fat acid glycidyl ester or theobroma oil, then active ingredient is scattered in wherein while stirring.Again uniform molten mixture is poured in traditional shaper, allowed its cooling, solidify.
Liquid absorption member comprises solution, suspension and emulsion.Can mention as an example and be used for the aqueous solution or the water-propylene glycol solution that enteron aisle is injected into outward.Contain in also can each cyclodextrin molecular with proper amt the hydroxypropyl α of 2-11 hydroxypropyl-, β-or γ-Huan Hujing, polyoxyethylene glycol such as PEG-2000 or propylene glycol in solution, fill a prescription, this solution also can contain water.Can prepare and be suitable for the aqueous solution for oral use by in water, adding active ingredient and adding the adequate colouration agent, flavouring agent, stablizer, sweeting agent, solubilizing agent and the thickening material that need.Be dispersed in to prepare in the water by the active ingredient that will be finely divided shape and be suitable for oral water suspending agent.Compound and hydroxypropyl-beta-cyclodextrin by formula I-IV can prepare particularly preferred water aqua medicine compounds in water.N.Bodor is at United States Patent (USP) 4,983, in 586, Pitha is at United States Patent (USP) 4,727, in 064, Janssen in international pharmaceutical patent application No.PCT/EP 84/00417, disclose use α-, β-and γ-Huan Hujing derivative, such as hydroxypropyl-beta-cyclodextrin.
Can accept carrier by hybrid medicine in water,, and have the medicine of the present invention of anti-mycotic efficiency amount can prepare pharmaceutical composition of the present invention to wherein adding such as hydroxypropyl-beta-cyclodextrin.The solution that so forms is filtered, remove moisture by known technology such as rotation vaporization or lyophilize if necessary.Can form solution about 15-35 ℃ temperature.Water herein generally is the water of sterilization, also can contain acceptable salt of medicine and buffer reagent, such as phosphoric acid salt, Citrate trianion and sanitas.The antifungal compound of formula I and the mol ratio of hydroxypropyl-beta-cyclodextrin about 1: 1-1: 80, preferred 1: 1-1: 2.The molar content of hydroxypropyl-beta-cyclodextrin generally is excessive,
Also have a kind of solid preparation, it is to become liquid preparation before use soon, or be used for oral, or be used for the injection.This plan changes the solid formulation of liquid form into, except that containing just like can at random containing cell walls active compound, particularly fungal cell wall inhibitor (such as fumanomycin), correctives, tinting material, stablizer, buffer reagent, artificial and natural sweeteners, dispersion agent, thickening material and solubilizing agent etc. the actives of The compounds of this invention.The used solvent of preparation liquid formulation can be water, isotonic water, ethanol, glycerine, propylene glycol, polyoxyethylene glycol etc. and their mixture.
Seemingly be used for the form that injection shape that vein, muscle or subcutaneous injection use generally is sterile solution, can contain salt or glucose so that solution has isotonicity.
The people is used for antimycotic surface preparation and is a kind of formula of medicine form, it contains the compound of formula 1, and (its concentration is generally about 20% weight of about 0.1-, preferred about 10% weight of about 0.5-) and no cytotoxic drug together can accept surperficially to use carrier, be coated onto it on ill skin and make moderate progress until symptom every day.
The people is used for the dosage of antimycotic oral preparations and is generally the about 50mg of every kg body weight about 1-every day, can once or divide and take the about 20mg of preferred every kg body weight about 2-every day for several times; The about 10mg of most preferably every kg body weight about 5-every day.
The people is used for the dosage of antimycotic injection formulations and is generally the about 20mg of every kg body weight about 0.5-every day, can once or divide administration for several times, the about 10mg of preferred every kg body weight about 1-every day.
Certainly, to change according to patient's sex, age, medical condition and by the infection severity that the clinical care doctor determines accurate dosage, administration frequency and the pitch time that is used for antimycotic The compounds of this invention.
General experiment
Prepare The compounds of this invention according to front view 1-1 X, below each embodiment commodity in use raw material all.
Embodiment 1a
2-acetoxyl group-1-(2,4 difluorobenzene base) ethyl ketone
In the mixture of 246g sodium-acetate, 3g NaI and 3L DMF, add 191g 2-chloro-2 ', 4 '-difluoro acetophenone (Aldrich chemical company).Stir this mixture 18 hours at 20 ℃, then it is concentrated into 1L.Raffinate is poured in rare HCl cold water solution of 6L and,, used anhydrous Na with salt water washing extraction liquid with the EtOAc extraction
2SO
4Be dried, filter the mixture that so forms, evaporated filtrate is left residue.Use CH
2Cl
2-hexane carries out silica gel chromatography to residue purifies, and obtains the 198g title compound.
Embodiment 1b
1-(2-(2,4 difluorobenzene base))-2-vinylcarbinol acetic ester
Suspension 131gMePh in churned mechanically anhydrous THF (270ml, 20 ℃)
3PBr.In 5 fens clock times earlier slowly, after add the NaN (Me of 393ml1M apace
3Si)
2THF solution, give it enough just ice-cooled simultaneously with holding temperature<23 ℃.The mixture that so obtains 20-24 ℃ of following stirring 1 hour is chilled to it-70 ℃, it is stirred 1/2 hour again.Add the solution of 65.5g embodiment 1a product in the anhydrous THF of 140ml then therein, adding speed will be enough slowly to keeping temperature to be lower than-70 ℃.Continue to stir the reaction mixture that forms like this and spend the night in cryostat, temperature rises to 20 ℃ therebetween, adds 50mlEtOAc in the suspension that so forms, and adds the 3L hexane then, places the mixture that forms like this about 15 minutes, and suction strainer is removed Ph
3PO is transferred to it in beaker when taking advantage of filter cake still moist.With the hexane of 1/2L fully develop filter cake and once more suction strainer with the hexane filtered liquid that 1: 1 (v/v) MeOH-water washing of 2 * 1L is merged together, use the salt water washing then removing the lingering section of product.Use MgSO
4Dry organic layer filters and evaporated filtrate, remaining red oil, add the 1.5L hexane and, be left glassy yellow solution, use earlier the 1/2L hexane by the diatomite layer suction strainer, use 1L15 again: 1 (v/v) hexane-EtOAc wash-out, carry out silica gel chromatography to yellow oil and purify.Merge each fraction uniformly, obtain 38.6g oily title compound.
Embodiment 1c
2-(2,4 difluorobenzene base)-2-vinylcarbinol
The product of 40g embodiment 1b is dissolved in the 400ml diox, adds the solution of 18g85%KOH in 315ml water.The mixture that vigorous stirring so obtains 1 hour is poured mixture into 1L Et then
2Among the O, separate water layer and use 250ml Et
2O extracts it, merges organic extract liquid, and first water washs it with salt solution again.Use anhydrous K
2CO
3Dry organic extract liquid to wherein adding the 10g coke, filters and evaporated filtrate again, the remaining light yellow oily title compound of 31.3g.
Embodiment 1d
(S) (-)-(2-(2-(2,4 difluorobenzene base)) Oxyranyle) methyl alcohol
33g is activated the 3_ molecular sieve powder be added to 13g L-(+)-diethyl tartrate at 2.3LCH
2Cl
2Solution in, the mixture that so forms is cooled to-5 ℃.In 2-3 minute, add the 15.4ml tetraisopropoxy titanium at 100ml CH
2Cl
2In solution, the mixture that will so form is chilled to-22 ℃ then.In 4-6 minute, add the solution of tertbutyl peroxide in pure isooctane of 109.5ml5.5M, the mixture that so forms is cooled to-25 ℃.Stirred these mixtures 25 minutes at-25 ℃, in 3-4 minute, add 2-(2,4 difluorobenzene base)-3-vinylcarbinol among the 40g embodiment 1c then at 100ml CH
2Cl
2In solution.Stirred the mixture that forms like this 41/2 hour at-27 ℃.Add 102ml by the saturated 30%NaOH aqueous solution of NaCl and stir the mixture that so forms, in 1/2 hour, make simultaneously temperature recovery arrive+10 ℃, to wherein adding the anhydrous MgSO of 100g
4Stirred 1/2 hour down with 33g diatomite and at+10 ℃, this mixture of suction strainer, and with 1.2L ether (Et
2O) filter cake that forms with the 1.5L toluene wash is again used anhydrous MgSO then
4The dry organic layer that merges.Filter this organic layer and vaporising under vacuum filtrate and form residue.This slag is dissolved in 1LEt
2Among the O, this mixture of suction strainer is also used the fresh Et of 200ml to remove insolubles by this filtrate of 100g silica gel suction strainer
2The O washing leaching cake.Vaporising under vacuum filtrate obtains the faint yellow thick title compound of 41g (94%), [α]
D 25-36.7 ° (c=1, MeOH); PMR (CDCl
3) d7.40 (m, 1H), 6.85 (m, 2H), 3.95 (m, 2H), 3.31 (d, 1H), 2.84 (d, 1H), 1.91 (m, 1H, commutative deuteriums).
Embodiment 2
(R)-(+)-(2-(2-(2,4 difluorobenzene base) Oxyranyle) methyl alcohol
According to the operation of embodiment 1d, just D-(-) diethyl tartrate with equivalent replaces L-(+) diethyl tartrate, obtains thick title compound [α]
D 25+ 33.9 ° (c=1, MeOH).With silica gel chromatography purification part crude compound, obtaining detecting with thin-layer chromatography (TLC) is uniform sample, [α]
D 25+ 40.0 ° (c=1, MeOH).
Embodiment 3
(R)-(-)-and 2-(2,4 difluorobenzene base)-3-(1,2, the 4-triazol-1-yl)-1, the 2-propylene glycol
With 8.91g1H-1,2,4 triazoles are dissolved in the 150ml dry DMF, and the mixture that so forms is cooled to 0-5 ℃.Add 2.81gNaH (60% oily dispersion liquid), and at room temperature stirred the mixture that so obtains 30 minutes, again to the product that wherein adds 10.9g embodiment 1d.Stirred the reaction mixture that forms like this 2 hours at 60-70 ℃, mixture is cooled to room temperature, to wherein adding 10ml water and vaporising under vacuum to obtaining residue.Residue is dissolved among 100ml water and the 900ml EtOAc.Use 250ml EtOAc aqueous layer extracted again.Twice EtOAc merged with the water washing of 100ml salt.Use anhydrous MgSO
4Dry EtOAc merges with the water washing of 100ml salt.Use anhydrous MgSO
4Dry EtOAc extraction liquid evaporates this extraction liquid.Use 10mlCH
2Cl
2The oily residue that development so obtains adds 100mlEt again
2O at room temperature stirs CH
2Cl
2-Et
2O mixture 1 hour filters and obtains 11.2g (75%) title compound, [α]
D 25-70.7 ° of (c=1, MeOH) mass spectrums (FAB): 256 (M+H)
+Use 5ml CH
3Product after CN recrystallization 1.0g filters obtains the 0.83g title compound, m.p.99-100 ℃;
-71.5 ° (c=1.0, MeOH); Ultimate analysis: calculate elemental analysis:Calculated for C
11H
11F
2N
3O
21/2CH
3CN; 52.27C, 4.57H.17.78N, 13.78F; Found:52.26C, 4.58H, 17.54N, 13.78F; PMR (DMSO) d3.25 (s, 1), 7.66 (s, 1), 7.33, (m, 1), 7.09 (t, 1), 6.90 (t, 1), 5.72 (s, 1), 5.05 (t, 1), 4.53 (s, 2) 3.61 (m, 2).
Embodiment 4
(S)-(+)-and 2-(2,4 difluorobenzene base)-3-(1,2, the 4-triazol-1-yl)-1, the 2-propylene glycol
According to the step of embodiment 3, just the product of the embodiment 2 of usefulness equivalent replaces the product of embodiment 1, obtains title compound, and Mp 95-101 ℃, [α]
D 25-70.O ° (c=1, MeOH) PMR is consistent with the structure of title compound with mass spectrum.
Embodiment 5
(R)-and 2-(2,4 difluorobenzene base)-3-(1,2, the 4-triazol-1-yl)-1,2-propylene glycol-1-methanesulfonates
The powdered product of 10.9g embodiment 3 is suspended in the 150ml methylene dichloride, is cooled to 0-5 ℃ to the mixture that wherein adds the 8.95ml triethylamine and will so obtain.In 10 minutes, add and be dissolved in 20mlCH
2Cl
2In the 3.64ml methylsulfonyl chloride.At room temperature stir the mixture that forms like this 1 hour, and it is cooled to 0-5 ℃, successively use 100ml cold (0-5 ℃) 5%KH
2PO
4, the extraction of cold (0-5 ℃) water of 100ml and 50ml salt solution.Use anhydrous MgSO
4Dry isolating organic layer, evaporation obtains 13.7g (96%) title compound [M+H+]
+PMR (CDCl
3) d7.95 (s, 1), 7.82 (s, 1), 7.53 (m, 1), 6.81 (m, 2), 4.84 (d, 1) .4.65 (d, 1), 4.46 (m, 2), 3.05 (s, 3).
Embodiment 6
(S)-and 2-(2,4 difluorobenzene base)-3-(1,2, the 4-triazol-1-yl)-1,2-propylene glycol-1-methanesulfonates
According to the method for embodiment 5, just the product of the embodiment 4 of usefulness equivalent replaces the product of embodiment 3, obtains title compound.PMR conforms to the structure of title compound.
Embodiment 7
(R)-and 1-(2-(2-(2,4 difluorobenzene base)) oxiranylmethyl radical)-1,2, the 4-triazole
The product of 13.7g embodiment 5 is dissolved among the anhydrous 200ml DMF, and the solution that will so form is cooled to 10-15 ℃, to wherein adding 1.71gNaH (60% oily dispersion liquid) and at room temperature stirred the reaction mixture so obtain 90 minutes, and vacuum concentration is to 50ml.To wherein adding 200ml cold water (0-5 ℃) and extracting with 3 * 200ml EtOAc.With the EtOAc extraction liquid that the water washing of 100ml salt merges, use anhydrous MgSO
4Dry EtOAc extraction liquid and with its evaporation obtains the 10.8g residue.To be dissolved in CH
2Cl
2Residue by 400g in advance with containing 1ml Et
3The CH of N/l
2Cl
2The MPLC level silicagel column that carries out the slurry filling and prepare is successively used 1LEtOAc; CH
2Cl
2(v/v) be 25,50 and 75 solution, use 2L EtOAc wash-out then.Merge branches at different levels and obtain 6.92g (68%) title compound.Mass spectrum (FBA) 238[M+H]
+PMR (CDCl
3) d7.97 (s, 1) 7.77 (s, 1), 7.07 (m, 1), 6.73 (m, 2); (4.73 d, 1), 4.41 (d, 1), 2.84 (d, 1), 2.78 (d, 1).
Embodiment 8
(S)-and 1-(2-(2-(2,4 difluorobenzene base)) oxiranylmethyl radical)-1,2, the 4-triazole
According to the method for embodiment 7, just the product of the embodiment 6 of usefulness equivalent replaces the product of embodiment 5, obtains title compound, and PMR conforms to the structure of title compound.
Embodiment 9
(5R-is suitable) and (5R-is anti-)-5-(2,4 difluorobenzene base)-2-oxo-5-((1H-1,2,4-triazol-1-yl) methyl) tetrahydrochysene-3-furancarboxylic acid ethyl ester
The 935ml diethyl malonate is dissolved among the anhydrous DMSO of 70ml.Divide two parts to add 2.24gNaH (60% oily dispersion liquid), and the reaction mixture that so forms in stirring at room 1 hour.Add the product of 6.65g embodiment 7 and stirred 18 hours at 50-55 ℃.Be chilled to room temperature, and pour reaction mixture into well-beaten 500ml KH
2PO
4, in 500ml salt solution and the 1L EtOAc mixture, separate and use 300ml EtOAc aqueous layer extracted again.EtOAc extraction liquid with 500ml salt water washing merging.Use anhydrous MgSO
4Dry EtOAc extraction liquid and evaporation obtain oily matter.Use CH
2Cl
2The MPLC level silicagel column that sent 400g to prepare this oily matter with hexane.Successively with 500ml hexane, 2L50%EtOAc: hexane (v/v), 2L EtOAc wash-out.Merge branches at different levels and obtain 8.66g (80%) title compound.Mass spectrum (FAB): 352[M+H]
+, PMR (CDCl
3) d8.08 (s, 2), 7.91 (s, 1), 7.71 (s, 1), 7.42 (m, 1), 7.13 (m, 1), 7.85 (m, 2), 4.60 (m, 4), 4.10 (m, 4), 3.49 (t, 1), 3.14 (t, 1), 3.89 (m, 4), 1.18 (m, 6).
Embodiment 10
(5S-is suitable) and (5S-is anti-)-5-(2,4 difluorobenzene base)-2-oxo-5-(1H-1,2,4-triazol-1-yl) methyl) tetrahydrochysene-3-furancarboxylic acid ethyl ester
According to the method for embodiment 9, just the product of the embodiment 8 of usefulness equivalent replaces the product of embodiment 7, obtains title compound.(PMR conforms to the structure of title compound with mass spectrum).
Embodiment 11
(R)-(-)-4-(2,4 difluorobenzene base)-2-methylol-5-(1H-(1,2, the 4-triazol-1-yl))-1,4 pentanediol
Be dissolved in the product of 8.5g embodiment 9 among the 125ml EtOH and add 2.15gLiCl.Stirred mixture is cooled to 0 ℃ also adds 1.92g NaBH in batches
4Stir this mixture 18 hours, and need not further cooling.In mixture, add 125ml MeOH and 10ml water and stirred 4 hours.With the mixture evaporate to dryness and with warm EtOH extraction precipitation.The evaporation extraction liquid adds 200ml THF to doing to residue, and the sound that the mixture that is stirring was carried out 15 minutes splits processing.Filtering mixt and evaporated filtrate.On silica gel, residue is carried out chromatogram and purify, use CH
2Cl
2-MeOH-NH
4OH (95: 5: 1) is wash-out (v/v/v), obtains the 3.9g title compound.Mass spectrum (FAB): 314 (M+H+); PMR (DMSO) d8.25 (s, 1), 7.69 (s, 1), 7.35 (m, 1), 7.13 (m, 1), 6.94 (m, 1), 6.27 (s, 1), 5.16 (t, 1), 4.44 (m, 4), 3.39 (m, 1), (3.20 m, 1), 3.05 (t, 2), 2.11 (m, 1), 1.52 (m, 1).
Embodiment 12
(S)-(+)-and 4-(2,4 difluorobenzene base)-2-methylol-5-(1H-(1,2, the 4-triazole))-1, the 4-pentanediol
According to the method for embodiment 11, just the product with the product replacement embodiment 9 of the embodiment 10 of equivalent obtains title compound.On silica gel, a part of crude product is carried out chromatogram and purify, use CH
2Cl
2-MeOH-NH
4The OH wash-out obtains detecting uniform product with TLC.This thing is soluble in water, filter and cooling drying filtrate, obtain title compound.[α]
D 25+54.50(c=1.0,MeOH)
Embodiment 13
(R)-(-)-and 4-(2,4 difluorobenzene base)-2-(((4-aminomethyl phenyl)-sulfonyloxy) methyl)-5-(1H-(1,2, the 4-triazolyl))-1,4-pentanediol-1-(4-methylbenzene) sulphonate
The product of 4.4g embodiment 11 is dissolved in 50ml CH
2Cl
2-THF (1: 1, v/v) in, add 4.7ml Et
3N and 180mg N, the N-Dimethylamino pyridine is chilled to 0 ℃ with solution.In batches to wherein adding the 5.9g Tosyl chloride, and stirred the reaction mixture that so forms 1/2 hour, then stirring at room 5 hours at 0 ℃.Add 100ml EtOAc and with the mixture suction strainer.Concentrated filtrate adds 150ml EtOAc, uses 5%KH
2PO
4Solution washing.Earlier with cold 5%NaHCO
3The aqueous solution washs organic layer with saturated brine again, uses anhydrous MgSO then
4Dry.Filtering mixt and evaporated filtrate.Chromatogram purification residue on silica gel with EtOAc-hexane wash-out, obtains 6.4g (73%) title compound, PMR (CDCl
3) d7.95 (s, 1), 7.67 (m, 5), 7.30 (m, 6) 6.70 (t, 2), 4.74 (d, 1), 4.53 (d, 1), 4.13 (m, 1), 3.97 (m, 1), 3.8 (m, 2), 2.43 (s, 6), 1.95 (m, 2), 1.77 (m, 1). mass spectrum (FAB): 622[M+H]
+.
Embodiment 14
(S)-(+)-and 4-(2,4 difluorobenzene base)-2-(((4-aminomethyl phenyl)-sulfonyloxy) methyl)-5-(1H (1,2, the 4-triazolyl))-1,4-pentanediol-1-(4-methylbenzene) sulphonate
According to the method for embodiment 13, just the product of the embodiment 12 of usefulness equivalent replaces the product of embodiment 11, obtains title compound, [α]
D 25+ 14.2 ° (c=1, MeOH).
Embodiment 15
(-)-(5R-is suitable)-5-(2,4 difluorobenzene base)-5-((1H-1,2,4-triazol-1-yl) methyl)-tetrahydrochysene-3-furfuralcohol-4-tosylate
The product of 6.3g embodiment 13 is dissolved in the 150ml toluene, formed solution is heated to 100 ℃.The NaH oil dispersion liquid that dropwise adds 2.4g60%, the reflux reaction mixture that forms like this is until finishing cyclisation (approximately 3-4 hour) then.Cooling mixture also separates solution with excessive NaH decant.Cold KH with 5%
2PO
4Solution washing solution, the evaporation organic layer forms residue, on silica gel residue is carried out chromatogram and purifies, and with acetone-hexane wash-out, obtains 1.6g (35%) as two kinds of a kind of title compounds that the product Semi-polarity is less, [α]
D 25-39.4 ° of (c=1, CHCl
3); PMR (CDCl
3) d8.09 (s.1), 7.88 (m, 3), 7.31 (m, 3), 6.81 (m.2), 4.52 (ASc, 2), (3.99 m, 1), 3.85 (m, 1), 3.70 (m, 1), 3.59 (m, 1), 2.49 (m, 2), 2.47 (s, 3), 1.90 (m, 1). mass spectrum (FAB): 450 (M+H)
+
Embodiment 16
(+)-(5S-is suitable)-5-(2,4 difluorobenzene base)-5-((1H-1,2,4-triazol-1-yl) methyl-tetrahydrochysene-3-furfuralcohol-4-tosylate
According to the method for embodiment 15, just the product of the embodiment 14 of usefulness equivalent replaces the product of embodiment 13, obtains title compound, [α]
D 25+ 43.3 ° of (c=0.3, CHCl
3) mp96-98 ℃.
Embodiment 17
(-)-((2R) suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) furans-3-yl) methoxyl group) phenyl)-1-piperazinyl) phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-ketone.
Tosylate and 4-(4-(4-nitrophenyl)-1-piperazinyl) phenol (United States Patent (USP) 4 with embodiment 15,791,111 embodiment 3a) be raw material, use summarize in the synoptic diagram V with J.Heeres etc. at J.Med.Chem.1984, Vol 27, and 898 among p894-900 and 900 described synthetic routes prepare title compound.
Embodiment 18
(((((5-(2 for 4-for 4-for 4-for (-)-((2R) suitable)-4-, the 4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-(1 (S)-methyl-2 (R)-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
A. (2R, 3R)-2,3-butyleneglycol-2-O-SEM ether
(2R, 3R)-2,3-butyleneglycol and 9.3g (55.7mmol) SEM-C is in the 55ml anhydrous DMF solution, at the NaH oil dispersion liquid (58.5mmol) that divided 4 parts to add 2.34g60% under 0 ℃ in 10 minutes in this solution to stir 4.95g (55mmol).The mixture that obtains 0 ℃ of stirring 4 hours, and at room temperature spend the night.The reaction mixture of muddiness is poured into 0.5L5%KH
2PO
4Solution is also with 2 * 300ml extracted with diethyl ether, and combined ether solution is washed once with distilled water, saturated salt, uses MgSO
4Dry also evaporation obtains colourless liquid.EtOAc/ hexane, 2L10%EtOAc/ hexane and 1L15%EtOAc with 1L7% on 350g silica gel carry out the flash chromatography purification, obtain 1.74g title compound (yield 14.4%).MS:(M+H)
+=221。
B. brosylization
At N
2Under the atmosphere, stirred 6 hours at the 2-O-SEM ether and the mixture of 0.97g (3.82mmol) 4-bromobenzene sulfonyl chloride in the 5ml anhydrous pyridine of envrionment temperature with 0.7g (3.18mmol) embodiment 18 (a).With 50ml frozen water dilution incarnadine pulpous state reaction mixture, with 2 * 25ml extracted with diethyl ether.Combined ether solution with 2 * 25ml1% copper-bath, distilled water, saturated brine washing, is used MgSO
4Dry also evaporation obtains incarnadine oily raffinate, carries out flash chromatography with the 1L10%EtOAc/ hexane and purify on the 50g silica gel, obtains colourless liquid bromo-benzene sulfonic acid ester (productive rate 72.9%) [α]
D 23=-3.69 ° of (CHCl
3C=1)
C. alkylated reaction
Under 80 ℃ and nitrogen atmosphere, stir the bromo-benzene sulfonic acid ester of 0.98g (2.23mmol) embodiment 18 (b), the 3H-1 of 0.69g (1.12mmol) embodiment 17,2,4-triazole-3-ketone and 0.37g (1.12mmol) the cesium carbonate mixture overnight (~20 hours) in the 12ml dry DMF.With 100ml frozen water diluted reaction mixture, extract with 2 * 50ml EtOAc.Merge organic solution and use distilled water, saturated salt to wash once, use MgSO
4Dry also evaporation obtains the brown solid residue.On 125g silica gel, carry out flash chromatography and purify, obtain 0.327g brown solid product (productive rate 35.7%) MS=(M+H) with the 1.2L80%EtOAc/ hexane
+=81.7
D.18 (c) acidic hydrolysis is a title compound
The mixture of SEM ether 6ml6N HCl solution in 6ml methyl alcohol with 0.32g embodiment 18 (c) stirred 4 hours at ambient temperature, and reduction vaporization.With 5ml frozen water dilution residue, and carefully use 10%Na
2CO
3The solution alkalization is until pH=8-9.With 2 * 25ml CH
2Cl
2The reaction mixture that extraction so forms with the saturated brine washing, is used MgSO again
4Dry also evaporation obtains brown solid.With the MeOH/CH of brown solid with 0.75L 4%
2Cl
2Wash-out obtains 0.26g brown solid title compound, productive rate 96.6% by the 50g silicagel column.MS=(M+H)
+=687;[α]
D 23=-23.65°(CHCl
3;c=1)。
Embodiment 19
(((((5-(2 for 4-for 4-for 4-for (-)-((2R) suitable)-4-, the 4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-1-(1 (R)-methyl-2 (R)-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
The a.Mitsunobu reaction
In 2-O-SEM ether, 2.1g (8.06g) triphenylphosphine and the solution of 1.2g (7.17mmol) p nitrobenzoic acid in the 30ml dry-out benzene of the 0.72g that is stirring (3.27mmol) embodiment 18 (a), dropwise adding 1.25ml (8.06mmol) diethylazodicarboxylate (DEAD) under 0 ℃.The clear thorough yellow solution that so forms becomes muddy, stirred the mixture 2 hours in envrionment temperature, and mixture is added on the 100g silicagel column, with 15%EtOAc/ hexane wash-out pillar, obtain 3-β-nitrobenzoyl acid esters (95% productive rate) that 1.5g has the absolute configuration of S, MS:219 (M
+-150), 252 (M
+-117).
B. the alkaline hydrolysis of p-nitrobenzoic acid ester
Stirred 1.12g (3mmol) embodiment 19 (a) p-nitrobenzoic acid ester and the solution of 3.5ml1N NaOH solution in 20ml methyl alcohol at ambient temperature 3 hours.Steam solvent with 10ml distilled water diluting residue, and with 2 * 20ml extracted with diethyl ether.Combined ether solution with the saturated salt washing is once used MgSO
4Dry also evaporation, the correspondent alcohol (~100%) that obtains 0.67g colourless liquid shape is directly used in next step reaction without making with extra care.
C. bromo-benzene sulfonic acid esterification, alkylation and acidic hydrolysis
According to embodiment 18 (c) and method (d), in 3 steps, prepare title compound with overall yield 32% by the product of embodiment 19 (b) and embodiment 17.MS:[M+H]
+=687;[α]
D 23=-23.65°(CHCl
3;c=1)
Embodiment 20
(-)-((2R)-suitable)-((((((5-(2 for 4-for 4-for 4-for 4-, the 4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-((S)-1-methyl-3-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
A. form TBDPS ether
(R)-(-)-1,3 in 3 minutes, add 3ml (11mmol) tert-butyl diphenyl chlorosilane (TBDPS) in butyleneglycol, the solution of 1.5g (22mmol) imidazoles in the 10ml dry DMF at 0 ℃ to 0.9g (10mmol).0 ℃ of stirred reaction mixture 4 hours, with the dilution of 50ml frozen water and with 2 * 30ml extracted with diethyl ether.With 50ml ether strip aqueous, the ethereal solution that merges is washed with saturated brine, use MgSO
4Dry also evaporation obtains colourless residue.On 150g silica gel, carry out flash chromatography and purify, obtain 2.87gTBDPS ether (87.5%) with 1.5L5%EtOAc/ hexane and 1L10%EtOAc/ hexane.MS:(M+H)
+:329;[α]
D 23=+0.64°(CHCl
3;c=1)。
B. bromo-benzene sulfonic acid esterification
TBDPS ether to 0.984g (3mmol) embodiment 20 (a) adds 0.845g (3.3mmol) 4-bromobenzene sulfonyl chloride in the solution of 7ml anhydrous pyridine.Method according to embodiment 18 (b) is carried out, is finished reaction and purifies, and the productive rate with 61.1% obtains 1.02g bromo-benzene sulfonic acid ester; (M+23)
+=569/571; [α]
D 23=+2.45 ° of (CHCl
3C=1).
C. alkylation
According to the method for embodiment 18 (c), make the compound reaction of bromo-benzene sulfonic acid ester and the embodiment 17 of 0.95g (1.74mmol) embodiment 20 (b), obtain the corresponding alkylate of 0.49g, productive rate 60.3%, MS:(M+H)
+925[α]
D 23=-32.27 ° of (CHCl
3C=1).
D. acidic hydrolysis
According to the method for embodiment 18 (d), the compound with 6N HCl solution hydrolysis 0.32g (0.35mmol) embodiment 20 (c) obtains 0.22g title compound (productive rate 92.4%); MS:M
+=686; (M+Na)
+=709; [α]
D 23=-38.52 ° of (CH
3Cl; C=1).
Alternatively, stirred the compound of 0.19g embodiment 20 (c) and the solution of 60mg (0.23mmol) Methanaminium, N,N,N-trimethyl-, fluoride in 5ml THF at ambient temperature 24 hours.Brown solution is concentrated into syrupy shape.On 50g silica gel with 2% and 4% the MeOH/CH of each 0.5L
2Cl
2Carry out the flash chromatography purification and obtain 0.11g title compound (productive rate 88.7%).
Embodiment 21
(-)-((2R)-suitable)-(((((5-(2 for 4-for 4-for 4-for 4-, the 4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-((R)-1-methyl-3-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
According to the method for embodiment 20, just (S)-(+)-1,3 butylene glycol with equivalent replaces corresponding R enantiomorph, is 31.8% in the overall yield of 4 steps, obtains title compound; MS=[M+H]
+=687.
Embodiment 22
(-)-((2R)-suitable)-(((((5-(2 for 4-for 4-for 4-for 4-, the 4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-(1 (S)-methyl-2-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
A. benzylization
(2R, 3R)-(-)-2,3 butyleneglycol is at the anhydrous CH of 40ml to 10g (111mmol) at 0 ℃
2Cl
2With add 1ml trifluoromethanesulfonic acid (FfOH) in the solution of 80ml hexanaphthene, dropwise add 21ml (113mmol) tribromo-acetyl imines acid benzyl ester again.Stir the soup compound that obtains at ambient temperature and spend the night, with dilution of 125ml hexane and filtration.The yellow soup compound of merging filtrate simmer down to.Yellow soup compound is used 1.5L7%EtOAc/ hexane, 2L15%EtOAc/ hexane and 2L25%EtOAc/ hexane, 1.5L10%MeOH/CH on 250g silica gel
2Cl
2Carry out flash chromatography and purify, obtain the single-benzyl ether (productive rate 74.5%) and the unreacted raw material of 2.03g of 11.88g raw material, MS:[M+H]
+: 181.
The b.Mitsunobu reaction
According to the method for embodiment 19 (a) the 2-single-benzyl ether of 5.4g embodiment 22 (a) is converted into 6.6g3-benzoic ether (productive rate 66.9%); MS:[M+H]
+=330.
C. alkaline hydrolysis
According to the method for embodiment 19 (b) product of 5.3g embodiment 22 (b) is carried out alkaline hydrolysis, (2R, 3S)-2, the single-benzyl ether of 3-butyleneglycol (productive rate 80.3%) (M+H) to obtain 2.33g
+=181; [α]
D 23=-23.75 ° of (CHCl
3C=1).
D. generate SEM ether
At ambient temperature, (2.82g, 21.8mmol) diisopropylethylamine is at the anhydrous CH of 30ml to the 3.14g that is stirring (17.44mmol) embodiment 22 (c) products and 3.8ml
2Cl
2In solution in add a 3.8ml (3.64g, 21.8mmol) SEM-Cl.Form smog; The yellow solution that obtains was stirred 20 hours.The orange-yellow reaction mixture of reduction vaporization, dispense solid residue between ether and water.With distilled water, saturated brine washing diethyl ether solution once, dry and concentrated with mg504, obtain crude product.With the 2L3%EtOAc/ hexane crude product is carried out flash chromatography and purify on 200g silica gel, obtain the 3-O-SEM ether of 5.3g embodiment 22 (c) product, (98% productive rate) is colourless liquid; MS:[M+H]
+=311.
E. hydrogen decomposes
Under barometric point to the compound of 5.25g (16.94mmol) embodiment 22 (d) and the hydrogenation mixture of 0.5g10%Pd/C in 150ml methyl alcohol 6 hours.Filtering catalyst is also used methanol wash in addition, concentrates the filtrate that merges and obtains colourless liquid.On 100g silica gel, liquid is carried out flash chromatography and purify, obtain 3.53g colourless liquid shape free alcohol (productive rate 95%) with the 2L10%EtOAc/ hexane; MS:174,103.
F. bromo-benzene sulfonic acidization
According to the method for 18 (d) product of 1g embodiment 22 (e) is converted into the corresponding bromo-benzene sulfonic acid ester of 1.52g, productive rate 76.2%; [α]
D 23=-1.53 ° of (CHCl
3C=1)
G. alkylated reaction
The bromo-benzene sulfonic acid ester of 1.48g embodiment 22 (f) and the product of embodiment 17 are reacted, obtain 0.75g 2-alkylation triazole-3-ketone, productive rate 54.3%; [α]
D 23=-32.69 ° of (CHCl
3C=1).
H. acidic hydrolysis
Product according to the method hydrolysis 0.7g embodiment 22 (g) of embodiment 18 (d) obtains 0.51g smectic solid title compound, productive rate 86.7%; [α]
D 23=-32.69 ° of (CHCl
3C=1)
Embodiment 23
(-)-((2R)-suitable)-(((((5-(2 for 4-for 4-for 4-, the 4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-(1 (S)-methyl-2-(S) hydroxypropyl)-3H-1,2,4-triazole-3-ketone.
The a.Mitsunobu reaction
According to product and the p-nitrobenzoic acid reaction of the method for embodiment 19 (a), obtain the 3.3g product, productive rate 98.8% with 1.99g (9.05mmol) embodiment 22 step e; MS=[M+H]
+=221.
B. alkaline hydrolysis
With the product in 7ml1N NaOAc hydrolysis 2.36g (6.4mmol) present embodiment a step, obtain 1.18g (2S, 3S)-2, the 3-O-SEM ether of 3-butyleneglycol, productive rate 83.7%.MS:[M+H]
+=221,[α]
D 23=+55.15°(CHCl
3;c=1)。
C. form the bromo-benzene sulfonic acid ester
According to the method for embodiment 18 (b), the product of 1.15g present embodiment step (b) is converted into the bromo-benzene sulfonic acid ester, obtain 3.47g bromo-benzene sulfonic acid ester, productive rate 97.7%.
D. alkylation and acidic hydrolysis
According to embodiment 18 (c) and operation (d), just replace the product of 18 (b) with the product of embodiment 23 (c), obtain title compound.
Embodiment 24
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2, the 4-triazol-1-yl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-((S)-1-ethyl-2 (S) hydroxypropyl)-3H-1,2,4-triazole-3-ketone
A. according to people such as W.C.Still at Tetrahedron Letters, 21, the method described in the 1035-1038 (1980) is converted into corresponding benzyloxy methyl esters with (S)-methyl lactate.
B. be reduced to aldehyde
Under-78 ℃ (dry ice/acetone batch) and nitrogen atmosphere, in the solution of ester at toluene of the present embodiment step (a) that 7.67g is stirring, dropwise add the DlBAL solution of 37.7ml1M.Add 1Oml methyl alcohol after 6 minutes, add the Rochelles salt brine solution again.After being warmed to room temperature, between EtOAc and water, distribute contained water.Separate organic phase, wash organic phase with water and use MgSO
4Drying, the thick aldehyde product of simmer down to, need not purify promptly is used in next step.
B. grignard reaction
Under-78 ℃ (dry ice/acetone batch) and nitrogen atmosphere, in the solution of the resulting thick aldehyde of present embodiment step (b) that is stirring, dropwise add the THF solution of the ethylmagnesium bromide Grignard reagent of 80ml1M at THF.After finishing interpolation, slowly allow the mixture that obtains be warmed to ambient temperature overnight, restir 48 hours.Add the Rochelles salt brine solution, between acetone and water, distribute the mixture that obtains then.Separate organic phase, wash with water, use MgSO
4Dry and concentrated.On silica gel, residue is carried out column chromatography and purify, obtain with EtOAc/ hexane (1: 10) wash-out
(i) the nonpolar alcohol of 2.31g colorless oil (2S, 3S), 31%;
The (ii) mixture of two kinds of alcohol of 1.23g, 41%;
(iii) 1.23g colorless oil polarity alcohol (2S, 3R), 16%.
C. polarity alcohol bromobenzene sulfonylation
Under room temperature and nitrogen atmosphere, 1.035g (4.1mmol) 4-bromobenzene sulfonyl chloride is added to the polarity of 0.605g (2.7mmol) the present embodiment step (b) that is stirring, and (2S, 3R) alcohol and 2.20g (5.9mmol) DMAP is at CH
2Cl
2Solution in.The mixture that obtains was stirred 12 hours, between EtOAc and water, distribute then.Separate organic phase, wash with water, dry and concentrated.On silica gel,, obtain the required bromine sulphonate (85%) of colorless oil with EtOAc/ hexane (1: 10) wash-out column chromatography purification residue.
D. alkylation and acidic hydrolysis
According to embodiment 18 (c) and operation (d), just use (2S, 3R) bromo-benzene sulfonic acid ester replacement used compound in embodiment 18 (c) of present embodiment step (c).Acidic hydrolysis produces white solid title compound, mp170-172 ℃.
Embodiment 25
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-((R)-1-ethyl-2 (S)-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
According to the operation of embodiment 24, just (2S, 3S) alcohol is converted into (2S, 3S) bromo-benzene sulfonic acid ester from embodiment 25 steps (b) nonpolar.Carry out alkylation and acidic hydrolysis SEM protecting group subsequently according to the method for embodiment 24 (d), obtain title compound.
Embodiment 26
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-((R)-1-ethyl-2 (R)-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
According to the operation of embodiment 24, just replace (s) methyl lactate of embodiment 24 steps (a) with (R) methyl lactate, step (c) and (d) use (2R, 3S) alcohol obtains title compound.
Embodiment 27
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-((S)-1-ethyl-2 (R)-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
According to the operation of embodiment 26, just step (c) and (d) use (2R, 3R) alcohol obtains title compound.
Embodiment 28
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-((R)-1-ethyl-3-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
At 0-5 ℃, (3R) dropwise add the LiAlH of 60ml 1M in the hydroxypentanoic acid methyl ester solution to 5.289 (40.0mmol) that are dissolved in the anhydrous THF of 100ml
4Solution in THF (60mmol).Allow solution be warmed to envrionment temperature, in the mixture that so forms, dropwise add 2.5ml water then, add NaOH and the 7.5ml water of 2.5ml15% again.Stirred the mixture so obtain 4 hours in envrionment temperature, remove by filter inoganic solids, evaporated filtrate obtains 4.31g (3R)-1,3-pentanediol.
B. generate 1-O-SEM ether
According to the operation of embodiment 18 (a), just (2R, 3R)-2, the 3-butyleneglycol obtains title compound in the product replacement of the present embodiment step (a) of usefulness equivalent.
The c.Mitsunobu reaction
According to the operation of embodiment 19 (a), just (2R, 3R)-2, the 2-SEM ether of 3-butyleneglycol obtains the corresponding p-nitrobenzoyl of 3.34g acid esters in the product replacement of the present embodiment step (a) of usefulness equivalent.
D. alkaline hydrolysis
According to the operation of embodiment 19 (b), just use the p-nitrobenzoyl acid esters of the present embodiment step (c) of equivalent, obtain 1.88g (3S)-1, the 1-O-SEM ether of 3-pentanediol.
E. bromobenzene sulfonylation, alkylation and acidic hydrolysis
According to embodiment 18 (b), (c) and operation (d), just use the product of the present embodiment step (d) of equivalent to replace the middle corresponding (2R that uses of embodiment 19 (b), 3R) 2, the 1-O-SEM ether of 3-butyleneglycol obtains 1.04g present embodiment title compound.[α]
D 23=-8.42°(CHCl
3;c=1)。
Embodiment 29
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl)-2,4-dihydro-2-((S)-1-ethyl-3-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
Produce 1-O-SEM-(3R)-1 according to embodiment 28 (a) and operation (b), the 3-pentanediol, operation according to embodiment 18 (b) is converted into 3R bromo-benzene sulfonic acid ester with it, makes the product alkylation of embodiment 17 with this 3R bromo-benzene sulfonic acid ester according to the operation of embodiment 18 (c).Method according to embodiment 18 (d) makes the product of formation like this carry out acidic hydrolysis, obtains the 368mg title compound, productive rate 90%; [α]
D 23=-47.11 ° of (CHCl
3C=1).
Embodiment 30
(2R-is suitable)-4-(4-(4-(4-((5-2,4-difluorophenyl)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-(the 1-hydroxyl-(2R)-butyl)-3H-1,2,4-triazole-3-ketone
A. prepare (2S)-1,2-butyleneglycol
To (the 2S)-3-butene-1 of 3g (0.034mmol) available from Eastman Kodak company, the solution hydrogenation of 2-glycol in 40ml ethanol spends the night in the presence of 300mg10%Pd/C.By the diatomite filtration reaction mixture that forms like this.With the filter cake that washing with alcohol so forms, the filtrate that evaporation merges obtains the 2.08g title compound, productive rate 68%.
B. form 1-O-SEM ether, bromobenzene sulfonylation, alkylation and acidic hydrolysis
According to the operation of embodiment 18 (a)-(d), just with the product of the present embodiment step (a) of equivalent replace embodiment 18 (2R, 3R) 2, the 3-butyleneglycol obtains title compound, [α]
D 23=-24.3 ° of (CHCl
3C=1).
Embodiment 31
(2R-is suitable)-4-(4-(4-(4-((5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl)-and the 3-furyl) methoxyl group) phenyl)-the 1-piperazinyl) phenyl)-2,4-dihydro-2-(the 1-hydroxyl-(2S)-butyl)-3H-1,2,4-triazole-3-ketone.
According to the operation of embodiment 30, just with (2R)-3-butene-1 of equivalent, 2-glycol (available from Eastman Kodak company) replaces (2S)-3-butene-1 of embodiment 30 steps (a), 2-glycol.After this operation according to embodiment 30 (b) produces title compound.[α]
D 23=-29.4°(CHCl
3;c=1)。
Embodiment 32
(-) (2R-is suitable)-4-(4-(4-(5-(2,4 difluorobenzene base)-tetrahydrochysene-5-(1H-1,2,4-triazol-1-yl methyl) phenyl methoxyl group furans-3-yl)))-and the 1-piperazinyl) phenyl-2,4-dihydro-2-((S)-1-ethyl-2 (S)-hydroxypropyl)-3H-1,2,4-triazole-3-ketone
A. by (S)-(O-phenyl) lactic acid pyrrolidone acid amides through selective reduction manufacturing (S)-2-(benzyloxy) propionic aldehyde
While stirring to 5g (0.0214mmol) according at Tetrahedron 1989, Vol 45, S-(O-benzyl) the lactic acid pyrrolidone acid amides of the described method preparation of p57-67 is dissolved in 20ml and adds the 4.25mlRED-AL (toluene solution of two (2-methoxy ethoxy) hydrogen calorize sodium of 3.4M in the solution in the refrigerative toluene in ice bath, available from Aldrich company, article No. #19,619-3).Stir this solution 5 hours, and used 2.5ml acetone earlier, use the 35ml2NHCl stopped reaction again, extract the mixture that so obtains with EtOAc.Water, NaHCO
3With salt water washing extraction liquid, use Na
2SO
4Drying, evaporation obtains title compound.
B. (S)-2-(benzyloxy)-N-formamido group tetrahydroform
With the propionic aldehyde of 1g (16.09mmol) step (a) be added drop-wise to the methylhydrazine that is dissolved in 5ml methyl alcohol (0.73g, 12.18mmol) in.Stirring the reaction mixture that so forms spends the night.Evaporation removes and desolvates, and stirs the residue of formation like this with ether.Remove by filter insoluble excessive methylhydrazine, remove ether and obtain residue, (v: v) wash-out is purified its chromatogram, obtains 805mg and has the active light yellow waxy solid title product of intensive ultraviolet with the 20%EtOAc/ hexane on silica gel; Ms[M+H]
+=207.
C.2-(3-(2S, 3S)-2 (benzyloxy) amyl group) formyl hydrazine
At the 3.0M diethyl ether solution that in the 10ml diethyl ether solution, adds 1.3ml (3.9mmol) ethylmagnesium bromide under 0 ℃ to the tetrahydroform of the 200mg that is stirring (0.97mmol) step (b).The reaction mixture that at room temperature will so obtain stirs and spends the night, and the water stopped reaction, separates organic layer, removing desolvates obtains residue, on silica gel with 30-50%EtOAc/ hexane (v: v) it is carried out chromatogram and purify, obtain 113mg oily title compound, productive rate 50%.S in the product, S isomer and S, the ratio of R isomer is 94: 6.In the presence of 1.2 equivalent two (front three is silica-based) ethanamides, repeat this reaction, S, S/S, the R ratio is brought up to 99: 1, MS:[M+H]
+=237
D. cyclization
The 17F of the product of stirring 156.3mg (0.66mmol) step (c) and 400mg (0.60mmol) synoptic diagram V and the solution of 1mol DBU (1,8-diazabicyclo (5,4,0) 11-7-alkene) in volume are 6 hours under 80 ℃; Temperature rises to 100-110 ℃, continues to stir under this temperature and spends the night.Allow reaction mixture be cooled to room temperature and proceed to stir at weekend.Evaporation removes and desolvates, with preparation TLC purification crude product (80%EtOAc/ hexane v: the benzylic ether that v) obtains 200mg spumescence solid present embodiment title product; MS:[M+H]
+=792.This cyclization is Mergelsberg, and people's such as Gala invention is disclosed in the U.S. Patent application book S.N. (proxy writes down #CD0475) that owns together.
E. hydrogenation decomposes
In being dissolved in the solution of 10ml methyl alcohol, the benzylic ether of 190mg (0.24mmol) steps d adds 40mg Pd/C and 4ml formic acid.With a balloon sealed reaction beaker, heated 4 hours down at 60 ℃.Remove by filter catalyzer by the diatomite cake, filtrate is poured in the cold water.Use NH
3The pH value of solution value that so forms is transferred to 4-5, with the EtOAc extraction mixture that forms like this.Separate organic layer and use Na
2SO
4Dry.Removing desolvates obtains crude product, with preparing TLC with its purification (5% methyl alcohol/CH
2Cl
2, v/v) obtain the title compound of 95mg brown solid present embodiment, productive rate 57%.MS:[M+H]
+=701,[α]-28.4(c=1.0,CHCl
3)。
Claims (15)
1. compound, its ester or ether or the acceptable salt of its medicine of formula 1 representative,
In the formula, X is F independently or is Cl, or an X another is Cl independently for F independently;
R
1By 1 or 2 straight or branched C that oh group replaces
4-C
5Alkyl.
2. according to compound or its ester or ether or the acceptable salt of its medicine, the wherein R of claim 1
1The straight or branched C that is replaced by at least one oh group
4-C
5Alkyl.
3. according to compound or its ester or ether or the acceptable salt of its medicine, the wherein R of claim 1
1Be the C that is selected from the hydroxyl replacement of following formula
4Or C
5Alkyl:
R wherein
4Be H, have asterisk (
*) carbon have R or the absolute configuration of S.
R wherein
5Be
5. according to the compound of claim 4, have following formula, or its ester or ether or the acceptable salt of its medicine.
6. according to the compound of claim 4, have the formula IV,
In the formula
Or
R wherein
6Be H, its polyether ester, phosphoric acid ester, sulfuric ester, heterocyclic ester, alkanoates, chain acid ester, amino acid ester, acid ester or the acceptable salt of medicine.
7. according to the compound of claim 6, R wherein
6Be polyether ester by the following formula representative,
In the formula, R
7Be H or C
1-C
6The straight or branched alkyl, R
8Be R
7Or
S is 1-6, and t is 1-6.
8. according to the compound of claim 6, R wherein
6Be phosphoric acid ester by the following formula representative,
In the formula, z is 0 or 1, and n=0-6, m are 0 or 1, R
7Be H or C
1-C
6Straight or branched alkyl, W are H or CH
2Ar or
Wherein Ar is phenyl or the phenyl that replaced by halogen, cyano group, nitro or trihalogenmethyl.
10. the pharmaceutical composition of control fungi infestation comprises that the compound of arbitrary aforementioned claim of antimycotic significant quantity reaches and its drug acceptable carrier together.
11., be used for oral or the enteron aisle external administration according to the pharmaceutical composition of claim 10.
12. each application of compound among the claim 1-9 is used to prepare the medicine that treats and/or prevents fungal infections in mannals.
13. according to the application of claim 12, medicine wherein is used for oral or the enteron aisle external administration.
14. the method for the formula of manufacturing III compound, wherein R
4Be
It is same that wherein each has the absolute space chemofacies of asterisk carbon atom, promptly all be S, S or R, R and do not contain S, R or R, S substantially, and wherein S or R lactate are converted into corresponding amide, it optionally is reduced to corresponding aldehyde, be converted into corresponding N-formamido group tetrahydroform then, this comprises and with general formula is
N-formamido group tetrahydroform can be with production
Under the Grignard reaction conditions of compound with ethylmagnesium bromide reaction, wherein have double asterisk (
*) the absolute stereo chemistry of deriving on the carbon is identical with single asterisk carbon basically, and wherein PG is conventional OH protecting group.
15. according to the method for claim 14, wherein PG is a benzyl.
16., be raw material wherein, in the presence of more than 1 equivalent two (trimethyl silyl) ethanamide, carry out grignard reaction with the S-methyl lactate according to the method for claim 14.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17108393A | 1993-12-21 | 1993-12-21 | |
US08/171,083 | 1993-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1142828A CN1142828A (en) | 1997-02-12 |
CN1064685C true CN1064685C (en) | 2001-04-18 |
Family
ID=22622452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94195025A Expired - Lifetime CN1064685C (en) | 1993-12-21 | 1994-12-20 | Tetrahydrofuran antifungals |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0736030B1 (en) |
JP (1) | JP2834889B2 (en) |
KR (1) | KR0179990B1 (en) |
CN (1) | CN1064685C (en) |
AT (1) | ATE204875T1 (en) |
AU (1) | AU681753B2 (en) |
BR (1) | BR1100154B1 (en) |
CA (1) | CA2179396C (en) |
CO (1) | CO4520281A1 (en) |
CZ (1) | CZ294823B6 (en) |
DE (2) | DE122006000004I2 (en) |
DK (1) | DK0736030T3 (en) |
ES (1) | ES2159623T3 (en) |
FI (1) | FI118470B (en) |
FR (1) | FR06C0009I2 (en) |
HK (1) | HK1008820A1 (en) |
HU (1) | HU225062B1 (en) |
IL (1) | IL112081A (en) |
LU (1) | LU91216I2 (en) |
MY (1) | MY130217A (en) |
NL (1) | NL300219I2 (en) |
NO (2) | NO316173B1 (en) |
NZ (1) | NZ278713A (en) |
PL (1) | PL181193B1 (en) |
PT (1) | PT736030E (en) |
SK (1) | SK283035B6 (en) |
TW (1) | TW377349B (en) |
WO (1) | WO1995017407A1 (en) |
ZA (1) | ZA9410142B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104370894A (en) * | 2014-10-21 | 2015-02-25 | 江苏恒盛药业有限公司 | Preparation process of amorphous posaconazole |
CN106432338A (en) * | 2015-08-08 | 2017-02-22 | 陕西合成药业股份有限公司 | Posaconazole derivative, synthesis and application in prolonged action preparation thereof |
CN106883221A (en) * | 2017-04-17 | 2017-06-23 | 兰州大学 | A kind of amorphous posaconazole and preparation method thereof |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU688455B2 (en) * | 1994-01-24 | 1998-03-12 | Janssen Pharmaceutica N.V. | Watersoluble azole antifungals |
ES2199291T3 (en) * | 1995-06-02 | 2004-02-16 | Schering Corporation | TETRAHYDROFURAN ANTIFUNGICS. |
US5698557A (en) * | 1995-06-19 | 1997-12-16 | Schering Corporation | Hydroxy-substituted antifungals |
AU6257396A (en) * | 1995-06-19 | 1997-01-15 | Schering Corporation | Tetrahydrofuran antifungals |
CN1209116A (en) * | 1995-12-20 | 1999-02-24 | 先灵公司 | Process for propn. of hydrazides |
US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
PE68898A1 (en) * | 1996-05-24 | 1998-11-10 | Schering Corp | ANTI-FUNGAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY |
US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
AU3483497A (en) * | 1996-06-28 | 1998-01-21 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
JP2000514059A (en) * | 1996-06-28 | 2000-10-24 | シェーリング コーポレイション | Oral composition containing a triazole antifungal compound |
AU5432698A (en) | 1996-11-12 | 1998-06-03 | Sepracor, Inc. | 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole |
WO1998021203A1 (en) * | 1996-11-12 | 1998-05-22 | Sepracor, Inc. | 2r,4s,s,r- and 2s,4r,s,r-hydroxyitraconazole |
EP0938484A1 (en) * | 1996-11-12 | 1999-09-01 | Sepracor, Inc. | 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole |
WO1998021213A2 (en) * | 1996-11-12 | 1998-05-22 | Sepracor, Inc. | 2r,4s,r,s- and 2s,4r,r,s-hydroxyitraconazole- and hydroxysaperconazole derivatives |
US5684197A (en) * | 1996-12-12 | 1997-11-04 | Schering Corporation | Process for preparation of hydrazides |
HU227744B1 (en) | 1997-02-11 | 2012-02-28 | Janssen Pharmaceutica Nv | Amino acid ester containing azole antifungals, process for their preparation, pharmaceuticals containing the same and intermediates |
US6043245A (en) * | 1997-09-25 | 2000-03-28 | Schering Corporation | Tetrahydrofuran antifungal phosphate |
IL134469A0 (en) * | 1997-09-25 | 2001-04-30 | Schering Corp | Tetrahydrofuran phosphate- and hydroxy esters as prodrugs for the corrersponding antifungal agent |
WO1999018111A1 (en) * | 1997-10-07 | 1999-04-15 | Schering Corporation | Crystalline antifungal glycine ester polymorph |
ATE263163T1 (en) * | 1997-10-07 | 2004-04-15 | Schering Corp | CRYSTALLINE FUNGICIDAL POLYMORPHOUS |
US6713481B1 (en) * | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
US5883097A (en) * | 1998-04-16 | 1999-03-16 | Schering Corporation | Soluble azole antifungal salt |
EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
US6147077A (en) * | 1999-04-29 | 2000-11-14 | Sepracor Inc. | 2R,4S-hydroxyitraconazole isomers |
BR0010279A (en) | 1999-05-04 | 2002-05-14 | Janssen Phamaceutica N V | antifungal ethers |
US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
US6448401B1 (en) | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
AU2002257104B2 (en) | 2001-04-03 | 2006-02-09 | Merck Sharp & Dohme Corp. | Antifungal composition with enhanced bioavailability |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7078526B2 (en) | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US7446107B2 (en) | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
MXPA05000232A (en) | 2002-06-21 | 2005-06-17 | Transform Pharmaceuticals Inc | Pharmaceutical compositions with improved dissolution. |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
ITMI20032020A1 (en) | 2003-10-17 | 2005-04-18 | Italfarmaco Spa | NEW AZOLIC ANTIFUNGAL AGENTS WITH DIFFERENT INTERACTION WITH METABOLIC CYTOCOMMAS |
PT1776109E (en) * | 2004-08-13 | 2009-03-25 | Schering Plough Ltd | Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid |
EP2130540A1 (en) * | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
EP2451805A1 (en) | 2009-07-09 | 2012-05-16 | Sandoz AG | A crystalline form of posaconazole |
WO2011158248A2 (en) * | 2010-05-12 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole |
EP2571847B1 (en) * | 2010-05-19 | 2016-09-21 | Sandoz AG | Process for the preparation of chiral hydrazides |
CN102906087B (en) * | 2010-05-19 | 2016-03-23 | 桑多斯股份公司 | Prepare the method for chiral triazole ketone |
RU2580318C2 (en) * | 2010-05-19 | 2016-04-10 | Сандоз Аг | Obtaining intermediate products for synthesis of posaconazole |
RU2585683C2 (en) * | 2010-05-19 | 2016-06-10 | Сандоз Аг | Cleaning of posaconazole and intermediate products for synthesis of posaconazole |
ES2893444T3 (en) | 2010-06-29 | 2022-02-09 | Merck Sharp & Dohme | Substituted Beta-Cyclodextrin Stabilized Intravenous Solution Formulations of Posaconazole |
CA2838051C (en) | 2011-06-16 | 2019-09-24 | Sandoz Ag | Process for the preparation of a chiral compound |
EP2789610A1 (en) | 2013-04-10 | 2014-10-15 | Sandoz Ag | Purification of Posaconazole Intermediates |
EP3024828B1 (en) * | 2013-07-25 | 2017-05-17 | Sandoz AG | Improved process for the preparation of crystalline form iv of posaconazole |
ITMI20132114A1 (en) | 2013-12-18 | 2015-06-19 | Djada Pharmaceutical Sa | A CRYSTAL SHAPE OF POSACONAZOLO |
CN105287403A (en) * | 2014-08-02 | 2016-02-03 | 陕西合成药业股份有限公司 | Freeze-drying composition of posaconazole prodrug and preparation method and application of freeze-drying composition of posaconazole prodrug |
ES2786374T3 (en) | 2014-12-05 | 2020-10-09 | Pulmocide Ltd | Antifungal compound |
HUE048843T2 (en) * | 2015-05-21 | 2020-08-28 | Pulmocide Ltd | Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl )-n -(2-hydroxycyclohexyl)benzamide, or a pharmaceutically acceptable salt thereof. |
CN106317032A (en) * | 2015-06-15 | 2017-01-11 | 重庆圣华曦药业股份有限公司 | Preparation method of high purity posaconazole |
JP7054381B2 (en) * | 2015-09-23 | 2022-04-13 | バイオコン・リミテッド | Process for the preparation of crystalline forms of posaconazole intermediates and amorphous posaconazole |
CN105606736A (en) * | 2016-01-27 | 2016-05-25 | 重庆华邦制药有限公司 | Method for separation determination of posaconazole intermediate Z1 and related substances of posaconazole intermediate Z1 |
CN105949278B (en) * | 2016-03-30 | 2019-12-06 | 南京曼杰生物科技有限公司 | Substituted tetrahydrofuran water-soluble derivative and application thereof |
WO2017032908A1 (en) | 2016-07-08 | 2017-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous posaconazole |
WO2018115319A2 (en) | 2016-12-23 | 2018-06-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases |
TR201620462A2 (en) | 2016-12-31 | 2018-07-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND PRODUCTION METHOD |
CN106967054A (en) * | 2017-03-30 | 2017-07-21 | 成都绿林科技有限公司 | A kind of preparation method of posaconazole |
CN108341754A (en) * | 2018-03-12 | 2018-07-31 | 扬子江药业集团有限公司 | Posaconazole impurity and its preparation method and application |
CN110938093B (en) * | 2018-09-21 | 2022-08-19 | 华创合成制药股份有限公司 | Posaconazole phosphate monocholine salt and preparation method and application thereof |
CN112778369B (en) * | 2019-11-05 | 2024-01-26 | 华创合成制药股份有限公司 | Triazole derivative and preparation method and application thereof |
CN113666915B (en) * | 2021-08-27 | 2022-08-16 | 江苏海洋大学 | Preparation method of posaconazole intermediate |
CN114315811B (en) * | 2021-11-19 | 2024-04-30 | 江苏恒盛药业有限公司 | Triazole analogue compound as well as preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004829A1 (en) * | 1987-11-20 | 1989-06-01 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
US5039676A (en) * | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
EP0539938A1 (en) * | 1991-10-30 | 1993-05-05 | Schering Corporation | Tri-substituted tetrahydrofuran antifungals |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
CA1292472C (en) * | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
-
1994
- 1994-12-20 PL PL94315169A patent/PL181193B1/en unknown
- 1994-12-20 IL IL11208194A patent/IL112081A/en active Protection Beyond IP Right Term
- 1994-12-20 DK DK95906620T patent/DK0736030T3/en active
- 1994-12-20 AT AT95906620T patent/ATE204875T1/en active
- 1994-12-20 DE DE1994628125 patent/DE122006000004I2/en active Active
- 1994-12-20 JP JP7517469A patent/JP2834889B2/en not_active Expired - Lifetime
- 1994-12-20 CN CN94195025A patent/CN1064685C/en not_active Expired - Lifetime
- 1994-12-20 ES ES95906620T patent/ES2159623T3/en not_active Expired - Lifetime
- 1994-12-20 ZA ZA9410142A patent/ZA9410142B/en unknown
- 1994-12-20 CO CO94057442A patent/CO4520281A1/en unknown
- 1994-12-20 AU AU15127/95A patent/AU681753B2/en not_active Expired
- 1994-12-20 DE DE69428125T patent/DE69428125T2/en not_active Expired - Lifetime
- 1994-12-20 TW TW083111949A patent/TW377349B/en not_active IP Right Cessation
- 1994-12-20 NZ NZ278713A patent/NZ278713A/en not_active IP Right Cessation
- 1994-12-20 SK SK826-96A patent/SK283035B6/en not_active IP Right Cessation
- 1994-12-20 MY MYPI94003426A patent/MY130217A/en unknown
- 1994-12-20 CZ CZ19961805A patent/CZ294823B6/en not_active IP Right Cessation
- 1994-12-20 EP EP95906620A patent/EP0736030B1/en not_active Expired - Lifetime
- 1994-12-20 WO PCT/US1994/014236 patent/WO1995017407A1/en active IP Right Grant
- 1994-12-20 HU HU9601709A patent/HU225062B1/en active Protection Beyond IP Right Term
- 1994-12-20 PT PT95906620T patent/PT736030E/en unknown
- 1994-12-20 CA CA002179396A patent/CA2179396C/en not_active Expired - Lifetime
-
1996
- 1996-06-20 NO NO19962616A patent/NO316173B1/en not_active IP Right Cessation
- 1996-06-20 FI FI962577A patent/FI118470B/en not_active IP Right Cessation
- 1996-06-21 KR KR1019960703319A patent/KR0179990B1/en not_active IP Right Cessation
-
1997
- 1997-03-06 BR BR1100154A patent/BR1100154B1/en unknown
-
1998
- 1998-07-29 HK HK98109516A patent/HK1008820A1/en not_active IP Right Cessation
-
2006
- 2006-01-27 LU LU91216C patent/LU91216I2/en unknown
- 2006-02-01 NL NL300219C patent/NL300219I2/en unknown
- 2006-02-10 NO NO2006002C patent/NO2006002I2/en unknown
- 2006-03-13 FR FR06C0009C patent/FR06C0009I2/fr active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004829A1 (en) * | 1987-11-20 | 1989-06-01 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
US5039676A (en) * | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
EP0539938A1 (en) * | 1991-10-30 | 1993-05-05 | Schering Corporation | Tri-substituted tetrahydrofuran antifungals |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104370894A (en) * | 2014-10-21 | 2015-02-25 | 江苏恒盛药业有限公司 | Preparation process of amorphous posaconazole |
CN106432338A (en) * | 2015-08-08 | 2017-02-22 | 陕西合成药业股份有限公司 | Posaconazole derivative, synthesis and application in prolonged action preparation thereof |
CN106883221A (en) * | 2017-04-17 | 2017-06-23 | 兰州大学 | A kind of amorphous posaconazole and preparation method thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1064685C (en) | Tetrahydrofuran antifungals | |
CN1073109C (en) | Tetrahydrofuran antifungals | |
CN1037267C (en) | Tri-substituted tetrahydrofuran antifungals | |
US5661151A (en) | Tetrahydrofuran antifungals | |
CN1251098A (en) | Pyrrole compounds, their prodn. and their use | |
JPH10512599A (en) | Triazole derivatives useful in therapy | |
CZ284318B6 (en) | Triazole derivatives, process of their preparation and use, as well as intermediates of the process | |
CN1100421A (en) | Process for preparation of a pharmaceutical composition containing a triazole derivative | |
CZ302012B6 (en) | Piperidine derivative and its use, process and intermediate for its preparation and pharmaceutical composition in which the derivative is comprised | |
US5714490A (en) | Tetrahydrofuran antifungals | |
US5703079A (en) | Tetrahydrofuran antifungals | |
HU211515A9 (en) | Optically active triazole derivatives and compositions | |
US5710154A (en) | Tetrahydrofuran antifungals | |
CN1182739A (en) | N-benzylazolium derivatives | |
JP2630877B2 (en) | Optically active triazole derivatives and compositions | |
EP1027349B1 (en) | Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent | |
WO1997000248A1 (en) | Hydroxyalkyl-substituted triazolones antifungals | |
CN1291610A (en) | Triazole derivative possessing anti-fungus activity | |
EP1088827B1 (en) | Azole derivatives or salts thereof | |
US5698557A (en) | Hydroxy-substituted antifungals | |
JPH10231296A (en) | Tetrahydrofuran-based antifungal agent | |
KR19980073433A (en) | Tetrahydrofuran antifungal agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: new jersey Patentee after: Schering Corporation Address before: new jersey Patentee before: SCHERING CORP (US) |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20141220 Granted publication date: 20010418 |